    
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  
Macitentan/ACT -064992 
Pulmonary Arterial Hypertension 
Protocol AC -055-303 OL  
SERAPHIN- OL: S tudy with an ERA in Pulmonary arterial H ypertension to 
Improve cli Nical outcome (Open Label)  
Long -term single -arm open -label extension study of the SERAPHIN study, to assess 
the safety and tolerability of macitentan/ ACT-064992 in patients with symptomatic 
pulmonary arterial hypertension 
Author(s): , DVM ,  BVSc ; , MD , MSc ; 
, Msc 
Document type : Clinical Study Protocol  
Study Phase : III 
EudraCT Number:  2007 -003694 -27 
Status and version:  Final Version 7 
Date : 17 July 2020  
Number of pages : 59 
Actelion number : D-20.250  
 
Confidentiality Statement  
The information provided herein contains Company trade secrets, commercial or financial information that the Company customarily holds close and treats as confidential. The information is being provided under the assurance that th e recipi[INVESTIGATOR_208136], 
regulations, rules, protective orders or otherwise . 
[STUDY_ID_REMOVED]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 2/[ADDRESS_448038] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  SPONSOR AND CRO CONTACT [CONTACT_359238] 16  
CH – 4123 Allschwil  
Switzerland  
Global Trial Leader  
  
  
Fax  
e-mail  
Clinical Trial Scientist  
 , DVM , BVSc  
  
Fax  
e-mail  
Clinical Trial  Physician  
 , MD , MSc  
  
Fax  
e-mail  
Drug Safety Physician  , MD  
  
Fax  
e-mail  
CENTRAL LABORATORY  
   Contact [CONTACT_359239]  
[ADDRESS_448039] Manager  
  
e-mail   
MEDICAL HOTLINE  Toll-free Hotline phone numbers for participating 
countries can be found in the site guidelines. 
For countries where no toll-free phone number is available, a toll phone number will be used.  
The medical hotline is intended for the use by [CONTACT_126999]. Patient should be asked to contact [CONTACT_359240].  
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 3/[ADDRESS_448040] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  SIGNATURE [CONTACT_42954] A CTELION PHARMACEUTICALS LTD 
Hereinafter called Actelion  
 Drug name/number  
Macitentan/ ACT -064992 
Disease  
Pulmonary arterial h ypertension. 
Protocol number . acronym , title  
AC-055- 303/SERAPHIN OL : 
Long- term single -arm open- label extension study of the SERAPHIN study, to assess the 
safety and tolerability of macitentan /ACT -064992 in patients with symptoma tic pulmonary 
arterial hypertension  
I approve the design of this study. Title    Name    [CONTACT_359280]    ___________  
 Clinical Trial  Bartosz  
Statistician   Jenner    ___________  
   
[COMPANY_003]
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 4/[ADDRESS_448041] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  SIGNA TURE PAGE FOR INVESTIGATOR(S)  
Drug name/ number   
Macitentan/ACT-064992  
Disease  Pulmonary a rterial h ypertension.  
Protocol number , acronym , title  
AC-055-303 OL/ SERAPHIN OL : Long-term single -arm open -label extension study of the 
SERAPHIN study, to assess the safety and tolerability of macitentan/ ACT -064992 in patients with 
symptomatic pulmonary arterial hypertension  
I agree to the terms and conditions relating to this study as defined in this protocol, the Case Report Form (CRF), and any other protocol -related documents. I fully understand that any changes 
instituted by [CONTACT_093](s) without previous agreement with the sponsor would constitute a protocol deviation, including any ancillary studies or procedures performed on study subjects (other  
than those procedures necessary for the wellbeing of the subjects).  
I agree to conduct this study in accordance with the Declaration of Helsinki principles, International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, and applicable regulations and laws. I will obtain approval by [CONTACT_215198] (IEC/IRB) prior to study start and signed informed consent from all subjects included in this study. If an amendment to the protocol is necess ary, I will obtain approval by [CONTACT_18369]/IRB 
and ensure approval by [CONTACT_208179], and I will re-consent the subjects (if applicable). I will allow direct access to source documents and study facilities to sponsor representative(s), particularly Clinica l Research Associate(s) and auditor(s), and agree to inspection by [CONTACT_359241]/IRB representative(s). I will ensure that the study treatment(s) supplied by [CONTACT_208181]/are being used only as described in this protocol. I will ensure that all subjects or legally designated representatives have understood the nature, objectives, benefits, implications, risks and inconveniences for participating in this study. During the conduct of the study, I will constantly monitor the risk/benefit balance for an individual subject. I confirm herewith that the sponsor is allowed to enter and utilize my professional contact [CONTACT_223145].  
Country 
Coordinating 
Investigator  [INVESTIGATOR_359221]/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 5/[ADDRESS_448042] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  TABLE OF CONTENTS 
 SPONSOR AND CRO CONTACT [CONTACT_359242]  ...................................................................2
 
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE  ..............................11  
PROTOCOL SYNOPSIS AC-055- 303/SERAPHIN OL  ..................................................13  
PROTOCOL  ......................................................................................................................18  
1 BACKGROUND AND RATIONALE  .......................................................................18  
1.1 Pulmonary hypertension ...............................................................................18  
1.2 Endothelin-1 and pulmonary hypertension ...................................................19  
1.3 Macitentan – Endothelin Receptor Antagonist  .............................................19  
1.3.1  Macitentan – Preclinical information  ...............................................19  
1.3.2  Macitentan – Clinical information  ....................................................20  
[IP_ADDRESS]  Phase I studies in healthy subjects  ..........................................20  
[IP_ADDRESS]  Phase II study in patients with essential hypertension  ............22  
[IP_ADDRESS]  Phase III study in patients with pulmonary arterial hypertension ............................................................................23
 
1.4 Study rationale ..............................................................................................23  
1.4.1  Medical background .........................................................................23  
1.4.2  Patient population  .............................................................................24  
1.4.3  Study design ......................................................................................24  
1.4.4  Dose selection  ...................................................................................24  
1.4.5  Treatment duration  ............................................................................24  
1.4.6  Primary endpoint ...............................................................................25  
1.4.7  Statistical hypotheses and sample size ..............................................25  
2 STUDY OBJECTIVES  ...............................................................................................25  
3 INVESTIGATIONAL PLAN  .....................................................................................25  
3.1 Study population ...........................................................................................26  
3.1.1  Patient population  .............................................................................26  
3.1.2  Inclusion criteria  ...............................................................................26  
3.1.3  Exclusion criteria  ..............................................................................27  
3.1.4  Concomitant medications  .................................................................27  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 6/[ADDRESS_448043] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  [IP_ADDRESS]  Prohibited concomitant medications  .......................................27  
3.2 Study drug .....................................................................................................28  
3.2.1  Study drug packaging, labeling  ........................................................28  
3.2.2  Study drug storage and dispensing ...................................................28  
3.2.3  Treatment dose and administration  ...................................................29  
3.3 Study drug discontinuation and study withdrawal .......................................29  
3.3.1  Study drug interruption or permanent dis continuation  .....................29  
3.3.2  Patient’s follow -up after study drug discontinuation ........................30  
3.3.3  Replacement policy  ...........................................................................30  
[IP_ADDRESS]  Patients  ....................................................................................30  
3.4 Treatment exposure, compliance and drug accountability ...........................30  
3.5 Treatment assignment  ...................................................................................30  
3.5.1  Treatment assignment  .......................................................................30  
3.5.2  Blinding ............................................................................................30  
3.5.3  Emergency procedure for unblinding ...............................................30  
3.6 Study endpoints ............................................................................................31  
3.6.1  Efficacy endpoints ............................................................................31  
3.6.2  Safety and tolerability endpoints ......................................................31  
3.7 Study assessments  .........................................................................................31  
3.7.1  Safety and tolerability assessments  ...................................................31  
[IP_ADDRESS]  Vital signs and body weight ....................................................31  
[IP_ADDRESS]  Laboratory assessments  ...........................................................31  
3.8 Visit and assessment schedule  ......................................................................35  
3.8.1  Enrollment visit  .................................................................................35  
3.8.2  Treatment period  ...............................................................................35  
[IP_ADDRESS]  Visits at 6 -monthly intervals (Visit 2, 3, etc.)  .........................35  
[IP_ADDRESS]  End-of-Treatment Visit (EOT) or Permanent 
discontinuation ........................................................................36  
3.8.3  End-of-Study (EOS) Visit or 28 -day follow -up ...............................36  
4 SAFETY DEFINITIONS AND REPORTING REQUIREMENT S ...........................37  
4.1 Summary table  ..............................................................................................37  
4.2 Adverse events ..............................................................................................37  
4.2.1  Definitions of adverse events ............................................................37  
4.2.2  Intensity of adverse events  ................................................................38  
4.2.3  Relationship to study drug ................................................................39  
4.2.4  Reporting of adverse events ..............................................................39  
4.2.5  Follow-up of adverse events .............................................................39  
4.3 Serious adverse events  ..................................................................................40  
4.3.1  Definitions  ........................................................................................40  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 7/[ADDRESS_448044] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  [IP_ADDRESS]  Serious adverse events  .............................................................40  
[IP_ADDRESS]  Hospi[INVESTIGATOR_059] – Prolongation of existing hospi[INVESTIGATOR_059]  .....40  
[IP_ADDRESS]  Serious adverse events related to study -mandated 
procedures ...............................................................................41  
4.3.2  Reporting of serious adv erse events  .................................................41  
[IP_ADDRESS]  Enrollment period  ....................................................................41  
[IP_ADDRESS]  Treatment period  .....................................................................41  
[IP_ADDRESS]  Reporting procedures ..............................................................42  
4.3.3  Follow- up of serious adverse events  .................................................42  
4.4 Pregnancy .....................................................................................................43  
4.4.1  Teratogenicity  ...................................................................................43  
4.4.2  Reporting of pregnancy ....................................................................43  
4.4.3  Follow-up of pregnancy ....................................................................43  
5 STATISTICAL METHODOLOGY AND ANALYSES  ............................................44  
5.1 Statistical analysis plan  .................................................................................44  
5.2 Analysis sets .................................................................................................44  
5.2.1  All-treated set  ....................................................................................44  
5.2.2  Safety set  ...........................................................................................44  
5.3 Primary efficacy endpoint ............................................................................44  
5.4 Secondary efficacy endpoints .......................................................................44  
5.5 Safety and tolerability endpoints ..................................................................44  
5.6 Exposure to study drug(s) .............................................................................45  
5.7 Baseline parameters  ......................................................................................46  
5.8 Exploratory analyses  .....................................................................................46  
5.9 Interim analyses  ............................................................................................46  
6 REFERENCES ............................................................................................................47  
7 PROCEDURES AND GOOD CLINICAL PRACTICE  .............................................51  
7.1 Procedures ....................................................................................................51  
7.1.1  Protocol amendments  ........................................................................51  
7.1.2  Monitoring ........................................................................................52  
7.1.3  Data management  .............................................................................53  
[IP_ADDRESS]  Data collection  .........................................................................53  
[IP_ADDRESS]  Database management and quality control ..............................53  
7.1.4  Recording of data and retention of documents .................................53  
7.1.5  Audit .................................................................................................54  
7.1.6  Handling of study drug(s) .................................................................54  
7.1.7  Publication and reporting of study results ........................................55  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 8/[ADDRESS_448045] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  7.1.8  Disclosure and confidentiality ..........................................................55  
7.1.9  Premature termination or suspension of the study  ............................55  
7.2 Good Clinical Practice  ..................................................................................56  
7.2.1  Ethics and Good Clinical Practice  ....................................................56  
7.2.2  Ethics Committee / Institutional Review Board  ...............................[ADDRESS_448046] OF TABLES  
 Table 1
 Visit and Assessment Schedule .......................................................................17  
Table 2  Study treatment adjustment in the event of ALT and/or AST elevations .......[ADDRESS_448047] OF FIGURES 
 Figure 1
 Study design ....................................................................................................26  
 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 9/[ADDRESS_448048] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  LIST OF ABBREVIATIONS 
6MWT  6-minute walk test  
AE Adverse event  
ALT  Alanine aminotransferase/serum glutamic pyruvic 
transaminase (SGPT) 
AST  Aspartate aminotransferase/serum glutamic oxaloacetic 
transaminase (SGOT) 
BP Blood pressure  
Cmax Maximum observed plasma concentration  
CRF  Case report form  
CRO  Contract research organization  
CYP  Cytochrome  
EC Ethics committee  
ECG  Electrocardiogram /graphy/graphic  
EOS  End-of-Study  
EOT  End-of-Treatment  
ERA  Endothelin receptor antagonist  
ET-1 Endothelin -1 
ETA Endothelin receptor A  
ETB Endothelin receptor B  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HRT  Hormone replacement therapy  
HIV Human immunodeficiency virus  
ICH International Council for Harmonisation  
IND Investigational New Drug  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 10/[ADDRESS_448049] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  IXRS  Interactive Voice /Web Recognition System  
IRB Institutional review board  
LFT Liver function test  
MedDRA  Medical Dictionary for Regulatory Activities  
MHRA  Medicines and Healthcare products Regulatory Agency  
OL Open label  
PAH  Pulmonary arterial hypertension  
PD Pharmacodynamic  
PH Pulmonary hypertension  
PK Pharmacokinetic  
PVR  Pulmonary vascular resistance  
RSI Reference Safety Information  
SAE  Serious adverse event  
SAP Statistical Analysis Plan  
t.i.d.  Three times a day  
ULN  Upper limit of normal  
WOCBP  Woman of c hildbearing p otential  
 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 11/[ADDRESS_448050] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE  
DOCUMENT  HISTORY  
Document  Date  
Amendment [ADDRESS_448051] 2007  
 
Amendment 6 ( 17 July 2020)  
Overall Rationale for the  Amendment : The purpose of this amendment is to update 
concomitant therapy section pertaining to newly identified drug- drug interactions (DDI) 
between macitentan and fluconazole (a dual moderate inhibitor of CYP3A4 and CYP2C9) from a pre -clinical study on implications of role of CYP2C9 in the metabolism of 
macitentan.  
A Protocol Amendment Summary of Changes Table for the current amendment is provided below.  
Section Nu mber and 
Name [CONTACT_11029]  
[IP_ADDRESS] Prohibited concomitant medications  Changes made to prohibited medications . 
• Current bullet point was modified as 
below: 
“Concomitant use of macitentan with 
strong inhibitors of CYP3A4 
(ketoconazole, itraconazole, 
voriconazole, clarithromycin, 
telithromycin, nefazodone, ritonavir, 
and saquinavir) or moderate dual 
CYP3A4/CYP2C9 inhibitors (e.g. , 
fluconazole, amiodarone) or co -
administration of a combination of 
moderate CYP3A4 (e.g., 
ciprofloxacin, cyclosporine, diltiazem, New DDI identified with implication on role of 
CYP2C9 in the metabolism of macitentan  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 12/[ADDRESS_448052] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  Section Nu mber and 
Name [CONTACT_359281], verapamil)  should be 
avoided.”  
• Following paragraph was added.  
“If patients are currently stable on a 
moderate dual CYP3A4/CYP2C9 
inhibitors (e. g., fluconazole, 
amiodarone) or co -administration of 
a combination of moderate CYP3A4 
(e.g., ciprofloxacin, cyclosporine, 
diltiazem, erythromycin, verapamil) 
and moderate CYP2C9 inhibitors 
(e.g., miconazole, pi[INVESTIGATOR_5329]), the 
patient may remain on current 
treatment per the investigator's 
discretion based on his/her clinical 
judgement and risk -benefi t 
assessment.”  
 
[IP_ADDRESS] Prohibited concomitant medications;6 References  A new reference was added to Section [IP_ADDRESS] and 
updated in the reference list.  To provide invest igators 
with some examples of CYP3A4 and CYP2C9 inhibitors . 
Abbreviations: CYP=cytochrome P450  
 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 13/[ADDRESS_448053] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  PROTOCOL SYNOPSIS AC- 055-303/SERAPHIN OL  
TITLE  Long -term, single -arm, open label extension study of the 
SERAPHIN study to assess the safety and tolerability of 
macitentan/ ACT -064992 in patients with symptomatic 
pulmonary arterial hypertension. 
ACRONYM  SERAPHIN OL: Study with an ERA  in Pulmonary arterial 
Hypertension to I mprove cliN ical outcome (Open Label).  
OBJECTIVES  To assess the long -term safety and tolerability of macitentan  
in patients with symptomatic pulmonary arterial hypertension (PAH).  
DESIGN / PHASE  Multicenter, open -label (OL) extension, single -arm, Phase III 
study 
STUDY PLANNED 
DURATION First 
patient  
First visit  Q4/[ADDRESS_448054] visit  Q1/[ADDRESS_448055] visit  Open  
CENTERS  
/ COUNTRIES  118 centers in 34 countries.  
PATIENTS / GROUPS  550 patients in one group.  
INCLUSION 
CRITERIA  • Signed informed consent prior to initiation of any study -
mandated procedure. 
• Patients with pulmonary arterial hypertension and having completed the event-driven study, AC-055- 302/SERAPHIN,  or 
Patients who have experienced a clinical worsening of PAH in AC-055-302/SERAPHIN and for whom a written approval to roll over into this study has been obtained from the Sponsor.  
• Women of childbearing potential must have a negative pre-treatment serum pregnancy test and must us e a 
reliable method of contraception during study treatment and for at least 28 days after study treatment termination.  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 14/[ADDRESS_448056] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  EXCLUSION 
CRITERIA  • Any major violation of protocol 
AC-055- 302/SERAPHIN.  
• Pregnancy or breast-feeding. 
• AST and/or ALT > 3 times the upper limit of the normal range. 
• Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence or psychiatric disease.  
• Known hypersensitivity to macitentan  or any of the 
excipi[INVESTIGATOR_840].  
CONCOMITANT 
MEDICATIONS  Prohibited  
• Endothelin receptor antagonists (other than study drug).  Note: If the investigator considers a switch to commercial Opsumit
®, treatment with commercial 
Opsumit® is allowed immediately after the EOT visit  but 
the subject must still present for an EOS visit after the follow -up period.  
If the investigator considers a  switch to another 
commercial ERA, treatment with that ERA must only 
begin after the follow-up period / EOS visit . 
• Specific immune suppressants: cyclosporine A and tacrolimus, everolimus, sirolimus (calcineurin or mTOR inhibitors).  
• Concomitant use of macitentan with strong CYP3A4 inducers (carbamazepi[INVESTIGATOR_050], rifampin, rifabutin and St. John’s wort) should be avoided. 
• Concomitant use of macitentan with strong inhibitors of CYP3A4 ( ketoconazole, itraconazole, voriconazole, 
clarithromycin, telithromycin, nefazo done, ritonavir, and 
saquinavir ) or moderate dual CYP3A4/CYP2C9 
inhibitors (e.g., fluconazole, amiodarone) or co -
administration of a combination of moderate CYP3A4 (e.g., ciprofloxacin, cyclosporine, diltiazem, erythromycin, verapamil) should be avoided. 
• Any investigational drug other than macitentan . 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 15/[ADDRESS_448057] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  STUDY PERIODS  Treatment period: until the approval of macitentan  for this 
indication is obtained or the sponsor decides to stop study 
AC-055- 303/SERAPHIN OL.  
Post-treatment safety follow -up: up to 28 days after study 
drug discontinuation.  
INVESTIGATIONAL 
DRUG  Macitentan  tablet oral administration / dose 10 mg / once 
daily. 
COMPARATIVE 
DRUG  Not applicable.  
TOLERABILITY / 
SAFETY ENDPOINTS  • Treatment -emergent AEs up to 28 days after study drug 
discontinuation. 
• Treatment -emergent SAEs up to 28 days after study drug 
discontinuation. 
• AEs leading to premature discontinuation of study drug. 
• Occurrence of liver function test (ALT and/or AST) abnormality (> 3 and ≤  5 × ULN; > 5 and ≤  8 × ULN; 
> 8 ×  ULN) and hemoglobin abnormality ( ≤ 8 g/dL; 
> 8 and ≤  10 g/dL) up to 28 days after study drug 
discontinuation.  
STATISTICAL 
METHODOLOGY  This study will not be individually analyzed, but only in 
combination with data from the AC -055- 302/SERAPHIN 
study. More precisely, the analysis set comprises (i) all 
patients in the AC -055- 303/SERAPHIN OL study plus (ii) all 
patients who received macitentan  during the 
AC-055- 302/SERAPHIN study and did not participate in the 
AC-055- 303/SERAPHIN OL study. In this set, the 
observation period for the individual patient starts at the time 
of the first administration of macitentan  and ends with the 
permanent discontinuation of macitentan  regardless of 
administration type (i.e., double blind or open label). 
The statistical evaluation of the safety and tolerability 
endpoints will be carried out descr iptively. 
STUDY 
COMMITTEES  A Steering Committee is involved in the study design and will 
provide guidance on the conduct of the study. 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 16/[ADDRESS_448058] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  An Independent Liver Safety Board is established to monitor 
the liver safety of macitentan including reviewing cases of 
confirmed elevations of aminotransferases > 3 × ULN.  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 17/[ADDRESS_448059] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  Table 1 Visit and Assessment Schedule 
PERIODS   TREATMENT PERIOD  FOLLOW -UP 
PERIOD  
VISITS  Enrollment  
(Visit 1)  Visit 2,3 , etc. End-of-Treatment (EOT)  End-of-Study 
(EOS)  
                                   TIMEPOINTS  
 
ASSESSMENTS Day 11 Month 6,  
and every 6 months 
thereafter  
± 2 weeks   Up to 28 days 
after study drug 
discontinuation  
Informed Consent  X    
Concomitant medication  X X X X 
Vital signs, Body weight  
Physical examination  Performed at each visit; Data will only be kept in patient ’s file   
Complete Laboratory Tests  X X X  
LFTs  X Recommended m onthly (+/−1 week)  
up to at least 28 days after End -of-Treatment  
Serum Pregnancy Test2  
(if applicable)  X X X  
Urine  Pregnancy Test2, 5  
(if applicable)   Required m onthly (+/− 1 week) 
up to at least [ADDRESS_448060] reminder and 
contraception counseling2  Required monthly (+/−1 week)  
up to at least 28 days after End -of-Treatment  
Study Drug Dispensing4 X X   
Adverse Events3  X X X X 
Serious Adverse Events  X X X X 
1The tests are not to be repeated if measured during the End -of-Treatment visit of study AC- 055-302/SERAPHIN that has been performed within 
4 weeks of this visit. 2Women of childbearing potential only; 3AE reporting and follow- up: all AEs up to [ADDRESS_448061] is performed.  
AE = adverse event; LFT = liver function test.
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 18/[ADDRESS_448062] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  PROTOCOL 
[ADDRESS_448063] serious chronic disorder of the pulmonary circulation is pulmonary arterial hypertension (PAH), a syndrome of diverse etiology and pathogenesis characterized by [CONTACT_359243] (PVR) potentially leading to right heart failure and death  [Barst  2004, McLaughlin 2004, D’Alonzo 1991
]. Pulmonary 
arterial hypertension is hemodynamically defined as a resting mean pulmonary arterial pressure greater than 25 mmHg with normal pulmonary capi[INVESTIGATOR_359222] (< 15 mmHg) [
McL aughlin 2004, Rubin 1997 ]. Numerous conditions are known to lead to 
or to be associated with the development of PAH. These conditions are classified into five groups based on their similar clinical presentation, pathology, pathophysiology, prognosis, and, most of all, similar therapeutic approach [
Simonneau 2004 ]. Pulmonary arterial 
hypertension may occur in the absence of a demonstrable cause (idiopathic or familial) [
Thomson 2003, McGoon 2004 ], or as a complication of congenital heart disease, systemic 
conditions such as connective tissue disease, particularly scleroderma [ Battle 1996 , 
Ungerer 1983, Tanaka 2002, Fagan 2004, Love 1990], HIV infection [Opravil 1997 , 
Petitpretz 1994 , Mehta 2000], sickle- cell disease [ Gladwin 2004 ], chronic liver disease 
[Kuo 1997, Castro 1996], obstructive or restrictive lung disease [ Weitzenblum 2005 , 
Chaouat 2005, Thabut 2005], thromboembolic disease [ Fedullo 200 1, Pengo 2004 ], 
sarcoidosis [ Shorr 2005], or as the result of the use of fenfluramine anorexigens  [Gurther 
1985 , Fishman 1999, Abenhaim 1996, Delcroix  1998 ]. 
Pulmonary arterial hypertension is associated with structural changes in both the pulmonary vasculature and the right ventricle. The changes in vascular structure involve three combined elements: vasoconstricti on, vascular -wall remodeling and thrombosis in 
situ [ Humbert 2004a
].  
Recent advances [ Farber 2004 ] in the understanding of the pathogenic factors leading to 
pulmonary vascular disease have led to the development of new therapi[INVESTIGATOR_359223] (the prostacyclin pathway, the endothelin pathway, and the nitric oxide pathway) [
Humbert 2004b ] that are believed to play pathogenic roles.  
The available therapi[INVESTIGATOR_359224], but they do not provide a cure, and in many patients the disease will progress. Pure vasodilators, such as calcium channel blockers, are effective only in a minority of patients who have an acute response to vasodilator testing. Seven  agents are currently approved for the treatment of PAH in the 
[LOCATION_002] and Europe. Intravenous prostacyclin (epoprostenol), other prostanoid analogues (i .e., beraprost, treprostinil, and iloprost), a dual endothelin receptors antagonist 
(bosent an), and more recently, phosphodiesterase type 5 inhibitors (sildenafil) and 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 19/[ADDRESS_448064] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  selective endothelin receptor antagonists (sitaxsentan and ambrisentan) have been shown to improve exercise capacity as assessed by [CONTACT_941] [ADDRESS_448065] (6MWT) in short- term 
randomized placebo -controlled trials.  
Despi[INVESTIGATOR_359225], however, PAH remains a serious life -threatening condition 
[Humbert 2004b, Humbert 2004a
]. Early recognition and an understanding of the  selection 
and timing of therapeutic options remain critical elements in the optimal management of patients with this disorder.  
1.2 Endothelin -1 and pulmonary hypertension  
Endothelin- 1 (ET- 1), a 21- amino -acid peptide, is one of the most potent vasoconstrictors  
and mitogens for smooth muscle and contributes to increased vascular tone and proliferation in pulmonary vasculopathy [ Galie 2004
].  
There are two distinct receptors for ET -1: endothelin receptor A (ET A) and endothelin 
recepto r B (ET B). The two receptors have unique binding locations and affinities for the 
endothelin peptide [ Banigni 1995, Massaki 1998 ]. The ET A receptors are expressed on 
pulmonary vascular smooth mus cle cells,  whereas ET B receptors are present both on 
pulmonary vascular cells and on smooth muscle cells.  
When activated, the ET A receptor located in pulmonary vascular smooth muscle cells 
mediates a potent vasoconstrictive response and ET B receptors on e ndothelial cells mediate 
vasodilatation via increased production of nitric oxide and prostacyclin [ Hirata 1993, de 
Nucci 1988 ]. ET -1 is also known to be a potent mitogen, with the ability to induce cell 
proliferation in vascular smooth muscle cells. It has been shown that both the ET A and ET B 
mediate the mitogenic action of ET -1 [Clarke 1989, Chua 1992, Davie 2002, Sugawara 
1996 ]. 
Laboratory and clinical investigations have clearly shown that ET -1 is overexpressed in 
several forms of pulmonary vascular disease. ET -1 is likely a major player in the 
vasodilator and vasocons trictor imbalance, as well as in the abnormal pulmonary vascular 
remodeling present in the development and progression of PH of various etiologies [Stewart 1991 , Giaid 1993
]. 
1.3 Macitentan  – Endothelin  Receptor Antagonist  
1.3.1 Macitentan  – Preclinical information  
Macitentan  is a new, orally active, non- peptide, potent dual ET A and ET B receptor 
antagonist selected for clinical development in PAH and other indications associated with an activated ET -system. Macitentan  shows dose -dependent efficacy similar to that 
observed with bosentan (Tracleer
®, the first ERA registered for the treatment of patients 
with PAH) in preclinical models of hypertension and PAH, but macitentan  is 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 20/[ADDRESS_448066] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  approximately [ADDRESS_448067] after cessation of treatment, 
or an increase in heart rate. In rats with monocrotaline -induced pulmonary hypertension, 
chronic oral administration of macitentan  increases survival and dose- dependently reduces 
pulmonary pressure, pulmonary vascular hypertrophy, and right ventricular hypertrophy, without decreasing systemic blood pressure. In preclinical safety studies, no effects on normal physiological functions or electrocardiographic (ECG) variables, including cardiac repolarizati on, were observed, 
with the exception of a decrease in arterial blood pressure observed in a cardiovascular study in dogs. Macitentan  has no genotoxic potential. In the pi[INVESTIGATOR_22735] 26-week and 39- week 
toxicity studies, the exposures in animals found at the no -observed- adverse- effect -level are 
above the anticipated clinical exposures and provide a margin of safety for studies in man. A study conducted in hairless rats showed that macitentan  is not phototoxic in vivo . 
Macitentan  does not bind relevantly to melanin. Reproductive toxicity studies showed that 
macitentan  is teratogenic without affecting male or female fertility. Teratogenicity is 
considered to be an ERA class effect.  
Macitentan  has been selected for further clinical development due to the following 
characteristics:  
• Its potency and selectivity for endothelin receptors 
• Its efficacy in preclinical models of hypertension and PAH 
• The absence of significant inhibitory effects on bile salt transport, suggesting an improved liver safety profile compared to bos entan  
• A pharmacokinetic profile consistent with once -daily dosing 
• A good safety and tolerability profile 
More detailed information on Macitentan  can be found in the Macitentan Investigator’ s 
Brochure [ Macitentan IB ]. 
1.3.2 Macitentan  – Clinical information  
[IP_ADDRESS] Phase I studies in healthy subjects  
During the Phase I program about [ADDRESS_448068] frequently reported adverse event (AE) was headache. No clear dose relationship could be discerned for any AE. However, in the single -ascending dose study, compared to 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 21/[ADDRESS_448069] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  subjects receiving placebo, subjects receiving a dose of 600 mg reported markedly more 
AEs (headache, nausea, vomiting, rhinitis, and others). A dose of 300 mg was identified as the maximum tolerated dose.  
Treatment with macitentan  up to 600 mg as a single dose and 30 mg as multiple doses for 
10 days (highest doses tested) was not associated with clinically relevant changes in systolic and diastolic blood pressures, heart rate, or ECG parameters and morphology.  Eight cases of asymptomatic increases in liver function tests (LFTs) were observed in the Phase I program. These increases in AST, ALT and/or GGT were below 2, 4, and 3 times the upper limit of normal (ULN), respectively. The increase in LFTs was not associated with any AE and resolved within 14 days of observation. In healthy male subjects, the plasma concentration -time profile of macitentan , administered 
as a capsules formulation, can be described by [CONTACT_359244] 8 hours after dosing. The apparent elimination half -
life was approximately 16 hours. After multiple dosing, the pharmacokinetics (PK) of macitentan  were dose -proportional over the dose range tested. Steady- state conditions were 
reached by [CONTACT_2006] [ADDRESS_448070] on the 
urinary 6β -hydroxycortisol/cortisol ratio, no signs of auto- induction were detected in this 
study. Macitentan  increased plasma ET -1 concentrations for all single doses from 5  mg upwards. 
When given as multiple doses, an increase in ET -1 levels was observed for all tested doses.  
Results from the food interaction study showed that macitentan  can be taken irrespective 
of food intake. Macitentan  did not influence the PK and pharmacodynamics (PD) of warfarin. Similarly, 
co-administration of warfarin with macitentan  appeared not to have an impact on the 
exposure of macitentan .  
There are no clinically relevant effects of sildenafil 20 mg t.i.d. on the  PK of macitentan  
and its metabolite (ACT -132577). Also, no effect of macitentan  was observed on the PK 
of sildenafil and its metabolite (N -desmethyl sildenafil).  
In the presence of the strong CYP3A4 inhibitor ketoconazole, an increase of approximately 
2-fold in area  under the curve  was observed for macitentan, while exposure to ACT -132577 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 22/[ADDRESS_448071] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  was reduced by 26%. Therefore, concomitant use of macitentan with strong inhibitors of  
CYP3A4 should be avoided. The results from the biocomparison study indicated a lowe r C
max of macitentan  of the 
tablets when compared to the capsule formulation, which was deemed not to be clinically relevant as the total exposure of macitentan  and ACT -[ADDRESS_448072] -132577 of 
the different formulations were found to be similar.  
More detailed information on macitentan  Phase I studies can be found in the Macitentan 
Investigator’s Brochure [ Macitentan IB ]. 
[IP_ADDRESS] Phase II study in patients with essential hypertension  
A Phase II dose- finding study was conducted over 8 weeks in 379 patients with mild to 
moderate essential hypertension. Four doses of ma citentan  (0.3, 1, 3, and 10 mg) and 
enalapril (20  mg) once daily were evaluated versus placebo. The primary efficacy endpoint 
was the change from baseline to Week  8 in mean sitting diastolic blood pressure (BP) at 
trough (i.e., [ADDRESS_448073] dose). This st udy has demonstrated that macitentan  is efficacious in reducing the blood pressure 
in subjects with mild to moderate essential hypertension. Treatment with the [ADDRESS_448074] doses of macitentan  tested were higher than that with 
enalapril 20 mg once a day (study was not powered to compare to enalapril). Most of the BP reduction with macitentan  was reached within 4 weeks of treatment. The PK/PD 
analysis supported the clinical findings, and indicated that the [ADDRESS_448075] 
one serious adverse event (SAE) were equally distributed across groups. There were no deaths.  
The study was terminated prematurely following the Sponsor ’s decision to break the blind 
for a safety evaluation of five cases of increased liver enzymes > 3 × ULN. These five cases 
occurred in the macitentan  groups, without obvious dose relationship (one, two, one, and 
one in the 0.3- mg, 1 -mg, 3 -mg, and 10- mg dose groups, respectively).  In three cases, there 
were other, plausible reasons for increased liver enzymes (pancreatic cancer, surgery with general anesthesia, and concomitant antibiotic therapy, respectively). All epi[INVESTIGATOR_359226] [ADDRESS_448076] that like other ERAs, macitentan  may cause liver enzyme elevations in 
some patients.  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 23/[ADDRESS_448077] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  More detailed information on macitentan  Phas e II studies can be found in the Macitentan 
Investigator’s Brochure [ Macitentan IB ]. 
[IP_ADDRESS] Phase III study in patients with pulmonary arterial hypertension  
A Phase III study in patients with PAH (AC -055- 302/ SERAPHIN) was conducted in 
742 patients randomized to placebo or macitentan 3 or 10 mg in a 1:1:1 ratio. In this event driven study, macitentan or placebo was administered in a double -blind fashion for up to 
3.6 years. Mean exposure to study treatment was 85.3 weeks for placebo patients (n = 249), 99.5 weeks for patients on 3 mg (n = 250) and 103.9 weeks for patients on 10 mg (n = 242). Macitentan, at both the 3 mg and 10 mg dose, decreased the risk of a morbidity/mortality event over the treatment period versus placebo. This risk was reduced by 45% in the 10 mg 
dose group (p < 0.0001). At 3 mg, the observed risk reduction was 30% (p = 0.0108).  A dose -dependent effect (p < 0.05 for either dose) was also observed in all secondary 
efficacy variables including exercise capacity assessed with the 6MWT, PAH symptoms assessed by [CONTACT_359245][INVESTIGATOR_47144]. Additionally, in a hemodynamic sub- study, the observed treatment effect of reduction in 
PVR after 6 months of treatment with macitentan 3 mg and 10 mg was 30.0% (97.5% confidence limits 17.9, 44.0) and 36.5% (97.5% confidence limits  21.7, 49.2), respectively. 
Treatment with macitentan was well tolerated. The number of AEs reported and patients discontinuing treatment due to AEs was similar across all groups. The overall incidence of elevations in liver aminotransfera ses was similar to placebo (4.5%, 3.6% and 3.4% 
incidence of ALT or AST > 3 ×  upper limit of the ULN in the placebo, macitentan 3 mg 
and macitentan 10 mg groups, respectively). In addition, no differences were observed between macitentan and placebo on fluid retention (edema). AEs associated with decreased hemoglobin was observed more frequently on macitentan 10 mg than placebo, with no difference in treatment discontinuation between groups.  
More detailed information on macitentan Phase III studies can be f ound in the Macitentan 
Investigator’s Brochure [ Macitentan IB ]. 
1.[ADDRESS_448078] 
selected for clinical development. In animal models of PAH and systemic hypertension, macitentan  shows dose -dependent efficacy, similar to that observed with bosentan. In rats 
with monocrotaline- induced PH, oral chronic macitentan  increased survival and dose -
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 24/[ADDRESS_448079] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  dependently reduced pulmonary pressure, pulmonary vascular hypertrophy, and right ventricular hypertrophy, without decreasing blood pressure [ Macitentan IB ]. 
Macitentan  was chosen for development in PAH because it is approximately [ADDRESS_448080] to liver enzyme injury [ Macitentan IB ]. 
The main objective of the AC -055- 303/SERAPHIN OL study, which will follow the 
AC-055- 302/SERAPHIN study, will be to assess the long -term safety and tolerability of 
macitentan  in patients with symptomatic PAH.  
1.4.[ADDRESS_448081] of  
• Patients who complete the event -driven treatment period of protocol 
AC-055-302/SERAPHIN as scheduled 
• Patients experiencing a clinical worsening of PAH, as defined in the AC-055-302/SERAPHIN protocol, and leading to permanent study treatment discontinuation in the AC-055-302/SERAPHIN study. The enrollment of these patients can only be performed after a formal request from the site and after written approval from the Sponsor 
1.4.3 Study design 
An open- label, non -comparative, multicenter, extension study following the 
AC-055- 302/SERAPHIN study to assess long -term safety and tolerability of macitentan  in 
patients with symptomatic PAH.  
The OL study design has been discussed and approved by [CONTACT_359246].  
1.4.4 Dose selection  
The p roposed dose (10 mg once daily) is the higher dose used in the Phase III study 
(AC-055- 302/SERAPHIN).  
1.4.5 Treatment duration  
Study treatment for each patient lasts from his/her enrollment date until the end of the trial i.e., until the earliest of: (i) the ap proval of macitentan  in this indication is obtained in the 
patient ’s country, or (ii) the sponsor decides to stop study AC -055- 303/SERAPHIN OL, 
or (iii) the patient ’s, investigator ’s or Sponsor’s decision to discontinue study drug. 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 25/[ADDRESS_448082] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  1.4.6 Primary endpoint  
No primary efficacy endpoint is considered for this OL extension study.  
1.4.7 Statistical hypotheses and sample size  
No statistical hypothesis is considered for this OL extension study.  
2 STUDY OBJECTIVES  
To assess long -term safety and tolerability of macitentan  in patie nts with symptomatic 
PAH.  
3 INVESTIGATIONAL PLAN  
This will be a multicenter, open -label, extension study to assess long -term safety and 
tolerability of macitentan  in patients with symptomatic PAH.  
550 patients (males or females aged 12 years or older) from the event -driven study 
AC-055- 302/SERAPHIN are enrolled in this Phase III OL study (see Section 1.4.2 ). The 
study will be conducted in 118 centers in 34 countries. The patients are rolled over from 
the event -driven study to the OL study without knowledge of their previous study drug 
(macitentan  or placebo). 
Enrollment in the AC -055-303/SERAPHIN OL study (OL Visit 1) should correspond to 
the last visit in the AC -055- 302/SERAPHIN study. If this is not possible, enrollment in the 
OL study must occur within 2 months of the AC -055- 302/SERAPHIN End-of- Treatment 
(EOT) Visit.  The target study drug tablet, 10 mg of macitentan , will be taken orally once daily, 
irrespective of food intake . 
At the end of the open -treatment period/discontinuation of treatment, a post- treatment 
safety follow -up period (28 days) will follow.  
A Steering Committee is involved in the study  design and will provide guidance on the 
conduct of the study. No interim analysis is planned. 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 26/[ADDRESS_448083] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  Figure 1 Study design 
 
Placebo    
 
Macitentan  3 mg   
 
Macitentan  10 mg  Macitentan  10 mg   
   Follow -up 
 Study 
AC-055-302 Study AC -055-303 / 
SERAPHIN OL  [ADDRESS_448084] of patients who complete the event -driven treatment 
period of protocol AC -055- 302/SERAPHIN as scheduled, and patients who have 
experienced a clinical worsening of PAH in AC -055- 302/SERAPHIN and for whom a 
written approval to roll over into this study has been obtained from the Sponsor. 3.1.2 Inclusion criteria  
• Signed informed consent prior to initiation of any study- mandated procedure.  
• Patients with pulmonary arterial hypertension and having completed the event- driven 
study, AC-055-302/SERAPHIN, or 
• Patients who have experienced a morbidity event and for whom a written approval to roll over into this study has been obtained from the Sponsor. 
• Pregnancy – Not allowed during the study:  
Wom en of childbearing potential* with a negative pre -treatment serum pregnancy 
test and who consistently and correctly use (from screening and up to 28 days after study treatment discontinuation) a reliable method of contraception with a Pearl index of <  1% (oral hormonal contraceptive, implant, vaginal hormone ring, 
intrauterine system, or tubal ligation only in combination with condom ), are 
sexually abstinent or have a vasectomized partner are allowed in the study . 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 27/[ADDRESS_448085] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  *A woman is considered to have childbearing potential unless she meets at least 
one of the following criteria:  
– previous bilateral salpi[INVESTIGATOR_8936] -oophorectomy or hysterectomy, 
– premature ovarian failure confirmed by a specialist gynecologist,  
– pre-pubescence, XY genotype, Turner syndrome, uterine agenesis, 
– fulfilling the criteria of postmenopausal at the screening of AC-055- 302/SERAPHIN, 
– age > [ADDRESS_448086] 2 years prior to Visit 1 of the 
AC-055- 303/SERAPHIN OL study  with amenorrhea for at least 
24 consecutive months prior to this visit and a serum follicle stimulating 
hormone level of > 40 IU/L  if the investigator has insufficient evidence 
that the woman is postmenopausal. 
3.1.3 Exclusion criteria  
• Any major violation of protocol AC -055- 302/SERAPH IN. 
• Pregnancy or breast-feeding. 
• AST and/or ALT > 3 times the upper limit of the normal range.  
• Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence, or psychiatric disease.  
• Known hypersensitivity to macitentan  or any of the excipi[INVESTIGATOR_840]. 
3.1.4 Concomitant medications  
All concomitant medications (ongoing, initiated, and discontinued) including PAH specific 
medications and diuretics, herbal drugs and implanted/vaginal hormonal contraceptives taken in the period between Visit 1 and up to End -of-Study ( EOS ) must be recorded on the 
Concomitant Medication pages of the CRF . 
Any dose changes  in PAH- specific medications only ( e.g., endothelin receptor antagonists, 
prostanoids, and phosphodiesterase type 5  inhibitors, initiation of continuous chronic 
oxygen therapy), must be recorded in the CRF. Dose changes of other medications may be 
recorded in the CRF at the investigator’ s discretion.  
[IP_ADDRESS] Prohibited conc omitant medications  
• Endothelin receptor antagonists (other than study drug)  Note: If the investigator considers a switch to commercial Opsumit
®, treatment with 
commercial Opsumit® is allowed immediately after the EOT visit but the subject must 
still present for an EOS visit after the follow -up period.  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 28/[ADDRESS_448087] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  If the investigator considers a switch to another commercial ERA, treatment with that ERA must only begin after the follow-up period / EOS visit. ), 
• Specific immune suppressants: cyclosporine A and tacrolimus , everolimus, sirolimus 
(calcineurin or mTOR inhibitors),  
• Concomitant use of macitentan with strong CYP3A4 inducers (c arbamazepi[INVESTIGATOR_050], 
rifampin, rifabutin and St. John’s wort) should be avoided, 
• Concomitant use of macitentan with strong inhibitors of CYP3A4 (ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir ) or moderate dual CYP3A4/CYP2C9 inhibitors (e.g. fluconazole, 
amiodarone) or co-administration of a combination of moderate CYP3A4 (e.g. ciproflo xacin, cyclosporine, diltiazem, erythromycin, verapamil) should be avoided, 
refer to the F ood and Drug A dministration  website [ FDA 2020],  
• Any investigational drug other than the macitentan . 
 If patients are currently stable on a moderate dual CYP3A4/CYP2C9 inhibitors (e.g. fluconazole, amiodarone) or co-administration of a combination of moderate CYP3A4 (e.g. ciprofloxacin, cyclosporine, diltiazem, erythromycin, verapamil) and moderate CYP2C9 inhibitors (e.g. miconazole, pi[INVESTIGATOR_5329]), the patient may remain on current treatment per the investigator's discretion based on his/her clinica l judgement and risk-
benefit assessment.  
3.2 Study drug  
3.2.1 Study drug packaging, labeling  
Patients who meet all inclusion criteria and none of the exclusion criteria will receive macitentan , 10 mg, in addition to their usual treatment. Actelion will provide study drug as 
tablets in childproof bottles containing 36 tablets. The study drug will be provided in : 
• One medication kit cont aining 6 bottles for a 6 month treatment period  or 
• [ADDRESS_448088] not be stored 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 29/[ADDRESS_448089] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  above 30 °C and must be protected from moisture. The study centers will be supplied with study drug according to the centers ’ needs, depending on the enrolled number of patients.  
Each center will have an individual stock of study drug, which will be re -supplied in a 
timely manner as soon as a pre- defined minimum level of study drug has been reached as 
controlled by [CONTACT_359247] e Voice/ Web Recognition System (IXRS). 
At each visit the medication kit or bottle numbers will be allocated to the subject through IXRS.  
Patients will receive study drug at enrollment (V isit 1 ) and at the [ADDRESS_448090] be documented in the patient ’s 
file. The patients will either receive a medication kit containing 6 bottles or 6 individual 
bottles covering a 6 months ’ treatment period  at scheduled visits (one bottle contains 36 
tablets). Patients may receive study drug at monthly visits (if applicable) if deemed 
necessary due to logistical reasons.  
Each medication kit or bottle will have a label with a tear -off part specifying the stud y 
protocol number and the batch number. At study drug dispens ing, the investigator or 
pharmacist (if applicable) must remove the tear- off label from the medication kit or from 
the individual bottle ( whatever applies ) and attach the label  to the Investigati onal Medicinal 
Product Label Dispensing Log. 3.2.[ADDRESS_448091] interests of the patient.  The interruption or premature discontinuation of study drug  might be triggered by [CONTACT_1149], 
a diagnostic or therapeutic procedure, an abnormal assessment (e.g., ECG or laboratory abnormalities), or for administrative reasons such as withdrawal of the patient’ s consent. 
The reason for study drug interruption or premature discontinuation must be documented in the case report form (CRF).  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 30/[ADDRESS_448092] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  Interruptions should be for less than 4 weeks; longer interruptions should lead to permanent discontinuation of study drug. A patient will be considered lost to follow up only after exh austing all means of contact. 
3.3.2 Patient ’s follow -up after study drug discontinuation 
If the patient is permanently withdrawn from the study, a complete EOT visit will be 
performed (see Section [IP_ADDRESS]) and the patient will be followed for [ADDRESS_448093] information on 
serious adverse events related to macitentan . If withdrawal is considered study 
drug- related, the patient will remain under the supervision of the investigator until 
satisfactory health has returned.  
3.3.3 Replacement policy  
[IP_ADDRESS] Patients  
Patients prematurely discontinued from the study drug for any reason will not be replaced . 
3.[ADDRESS_448094] be kept during the study. Study drug accountability is performed on an ongoing basis by [CONTACT_359248]. Patients are asked to return all unused study drug (including empty bottles and cartons) at each visit. At the conclusion of each patient ’s participation in the study, all 
remaining drug supplies must be returned to the Sponsor for an accurate accounting of 
delivered and returned drugs. All remaining drug supplies shall be collected and returned to the Sponsor for destruction by [CONTACT_307890]. Destruction must be documented. 
3.5 Treatment assignment 
3.5.1 Treatment assignment  
Treatment is macitentan  10-mg tablets for all patients.  
3.5.2 Blinding  
Not applicable. 3.5.3 Emergency procedure for unblinding  
Not applicable.  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 31/[ADDRESS_448095] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  3.6 Study endpoints  
3.6.1  Efficacy endpoints  
Not applicable.  3.6.2 Safety and tolerability endpoints  
• Treatment -emergent AEs up to 28 days after study drug discontinuation. 
• Treatment -emergent SAEs up to 28 days after study drug discontinuation. 
• AEs leading to premature discontinuation of study drug. 
• Occurrence of treatment -emergent increase in ALT and/or AST up to 28 days after 
study drug discontinuation: 
– > 3 and ≤  5 × ULN  
– > 5 and ≤  8 × ULN  
– > 8 ×  ULN  
• Occurrence of treatment -emergent hemoglobin abnormality up to 28 days after study 
drug discontinuation: 
– ≤ 8 g/dL 
– > 8 and ≤  10 g/dL 
3.7 Study assessments 
The assessment performed at the EOT Visit for the event -driven study 
(AC-055- 302/SERAPHIN) should not be repeated at enrollment (Visit 1) in the OL study 
if the EOT Visit was performed within [ADDRESS_448096] occur within 2 months of the AC-055- 302/SERAPHIN EOT Visit.  
3.7.1 Safety and tolerability assessments  
The definitions, reporting and follow -up of AEs, SAEs and potential pregnancies are 
described in Section 4. 
[IP_ADDRESS] Vital signs and body weight 
Vital signs (blood pressure and heart rate) and body weight will be assessed at the 6 -
monthly visit s. The data will be kept in the patient’ s file (i.e. , not recorded in the CRF).  
[IP_ADDRESS] Laboratory assessments  
[IP_ADDRESS].1 Type of laboratory 
Both Central and Local Laboratories are used in the study. Until approval of the Global Protocol version 5, blood sample analyses (hematology and 
biochemistry) were  performed by [CONTACT_359249]. For all the blood samples analyzed 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 32/[ADDRESS_448097] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  from beginning of the study up to approval and implementation of the Global Protocol version 5, local laboratory reports present at the site were  used to record protocol mandated 
laboratory results in th e Actelion database. I f re-test or unscheduled blood samples had 
been  analyzed between regular visits for the purpose of monitoring an AE, the results of 
the analyses were  also be recorded in the Actelion database.  
After approval and implementation of Global Protocol version 5, the hematology and  
biochemistry blood samples a re to be collected at site and sent to the Central Laboratory 
for analysis whenever possible  (see contact [CONTACT_215227] 2). The Central Laboratory 
reports will b e sent  to the Investigator. Any complete or partial re -test blood sample  
deemed necessary to follow -up an AE  or to verify an unexpected abnormal value should 
also be sent to  the Central Laboratory. 
Under specific circumstances (e.g., patient lives far away  from the site and cannot return 
every month), laboratory samples could be drawn in a local laboratory using Central Laboratory kits which will be sent to and analyzed by [CONTACT_15622]. 
In the exceptional event  (e.g., patient is admitted in  a different hospi[INVESTIGATOR_359227]) where 
a local laboratory is utilized for analysis of blood samples, data of these tests must  be 
recorded in the Actelion database.  
The results (whether obtained via L ocal or C entral Laboratory) will be kept in the patient’ s 
file. Any c linically significant marked laboratory abnormalities must be reported by [CONTACT_359250]/or SAE as appropriate  (see Section 4).  All Laboratory reports 
must be reviewed, signed and dated upon receipt. Any pregnancy occurring during the treatment period and up to [ADDRESS_448098] be reported immediately to the Actelion Drug Safety Department using the Actelion Pregnancy Form (see Section 4). 
Details about collection and shipment of samples, and the reporting of results and abnormalities, can be found in the laboratory manual provided to the investigator. [IP_ADDRESS].[ADDRESS_448099] visit in AC -055- 302/SERAPHIN can be used at the 
AC-055- 303/SERAPHIN OL Enrollment Visit (OL Visit 1). The tests should not be 
repeated if enrollment in AC -055- 303/SERAPHIN OL is within [ADDRESS_448100] 
known r esults.  
Hematology and blood chemistry  
Hematology and blood chemistry tests will be performed at the Enrollment Visit (OL Visit 1), if it occurs more than [ADDRESS_448101] visit in AC -055-302/SERAPHIN, and then 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 33/[ADDRESS_448102] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  every 6 months until EOT . They include hemoglobin, hematocrit, platelet, leukocyte and 
erythrocyte counts, liver aminotransferases (AST/ALT), alkaline phosphatase, total and direct bilirubin, creatinine, urea, glucose, sodium, potassium, and albumin.  
Pregnancy test  
A serum pregnancy test for women of childbearing potential (WOCBP) must be performed 
at the Enrollment Visit (OL Visit 1), if it occurs more than [ADDRESS_448103] visit in 
AC-055- 302/SERAPHIN, and then every [ADDRESS_448104] call each WOCBP once per month to: 
• remind her to perform an urine pregnancy test and 
• collect the outcome of the urine pregnancy test  
During eac h visit at site  / at each tele phone call , it must be verified whether the method of 
contraception used previously is still valid, in accordance to the protocol and correctly used by [CONTACT_423]. For prepubescent women, childbearing potential must be assessed at each visit / tele phone call  and the women must be advised to use reliable methods of 
contraception as soon as childbearing potential has been established.  Urine pregnancy test kits will be provided by [CONTACT_359251]. Liver aminotransferase monitoring in all patients  
Liver aminotransferase levels must be measured at the Enrollment Visit (OL Visit 1), if it occurs more than [ADDRESS_448105] visit in AC -055-302/SERAPHIN, and then every [ADDRESS_448106] 28 days after 
EOT  but it is at the investigator ’s discretion to decide (taking into account the patient’ s 
medical history and AEs) if those additional monthly tests are required/justified.  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 34/[ADDRESS_448107] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  Table 2 Study treatment adjustment in the event  of ALT and/or AST 
elevations 
ALT and/or AST  Treatment and monitoring recommendations  
> 3 and ≤ 8 × ULN  Confirm by [CONTACT_359252]. If confirmed, 
interrupt treatment, monitor aminotransferase, bilirubin 
and alkaline phosphatase levels weekly  until levels return 
to pre -treatment values . If the aminotransferase values 
return to pre -treatment levels re-introduction of study 
treatment can be considered. Interruptions should be for 
less than 4 weeks; longer interruptions should lead to 
permanent discontinuation of study drug. 
Re-introduction of s tudy treatment after treatment 
interruption should only be considered if the potential 
benefits of treatment with macitentan  outweigh the 
potential risks and when liver aminotransferase values are 
within pre -treatment levels. The advice of a hepatologist 
is recommended.  
Liver aminotransferase levels must then be checked within 3 days after re-
introduction, then again after a further 
2 weeks and thereafter according to the recommendations above (i.e., at monthly intervals). 
ULN = Upper Limit of Normal  
 
In case of associated clinical symptoms of liver injury, e.g., nausea, vomiting, fever, 
abdominal pain, jaundice, unusual lethargy or fatigue, flu- like syndrome (arthralgia, 
myalgia, fever), and/or increases in total bilirubin ≥  2 × ULN or aminotransferases > 8 × 
ULN, treatment must be stopped and re -introduction of study treatment is not to be 
considered. Aminotransferase, bilirubin and alkaline phosphatase levels must be monitored 
weekly after study drug discontinuation until value s return to pre -treatment le vels. 
Other diagnoses should be considered and ruled out by [CONTACT_180495] (e.g., viral hepatitis, mononucleosis, toxoplasmosis, cytomegalovirus, etc.).  A 
“SERAPHIN LFT increase questionnaire ” must be completed for confirmed elevations of  
aminotransferases > 3× ULN.  
All LFT abnormalities leading to study drug discontinuation must be recorded as AEs (see Section 4). 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 35/[ADDRESS_448108] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  3.8 Visit and assessment schedule  
For a tabulated summary of all visits and assessments described in the following sections see Table 1
. 
3.8.1 Enrollment visit  
It is the responsibility of the Investigator to obtain written informed consent from each patient participating in this OL study after adequate explanation of the aims, methods and objectives of the study.  The visit includes: • Patient information and consent form signature 
• Physical examination  
• Measurement of vital signs and body weight 
• Laboratory tests including: 
– Complete laboratory tests including:  o Hematology (including hemoglobin), 
o Blood chemistry (including LFTs),  
– Serum pregnancy test (for women of childbearing potential), NOTE: monthly monitoring from enrollment and up to at least 28 days after permanent discontinuation of the macitentan  treatment,
 
• Concomitant medication  
• Dispensing of study drug. 
The tests are not to be repeated if they were measured during the  EOT Visit in 
AC-055- 302/SERAPHIN, and if that visit was performed within 4 weeks of this visit.  
3.8.2 Treatment period  
After approval and implementation of Global Protocol version 6 , LFTs  and pregnancy (for 
women of childbearing potential) will be assessed as o utlined in Table 1 . 
During this period, AEs/ SAEs  and concomitant medication will be reported in the CRF.  
[IP_ADDRESS] Visits at 6 -monthly intervals (Visit 2, 3 , etc.)  
After the OL Visit 1, all following visits are scheduled every 6 months ± 2 weeks. The morning dose of the study drug should be taken as usual. These visits include:  
• Physical examination  
• Measurement of vital signs and body weight 
• Laboratory tests including: 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 36/[ADDRESS_448109] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  – Complete laboratory tests including:  
o Hematology (including hemoglobin), 
o Blood chemistry (including LFTs),  
– Serum pregnancy test (for women of childbearing potential), NOTE: monthly monitoring from enrollment and for up to at least 28 days after permanent discontinuation of the macitentan  treatment,  
• AEs and SAEs since last visit will be reported in the CRF  
• Concomitant medication  will be reported in the CRF  (for details see Section 3.1.4
) 
• Dispensing of study drug macitentan .  
[IP_ADDRESS] End-of-Treatment Visit ( EOT ) or Permanent discontinuation  
Actelion will notify all sites when an EOT  Visit should be planned. At the end of the OL 
study (see Section 1.4.5 for definition), the EOT Visit is scheduled for all patients. Any 
visit formerly scheduled within [ADDRESS_448110] also undergo the EOT Visit  
as soon as the treatment is discontinued . 
This visit includes:  
• Physical examination  
• Measurement of vital signs and body weight 
• Laboratory tests including: 
– Complete laboratory tests including:  
o Hematology (including hemoglobin), 
o Blood chemistry (including LFTs),  
– Serum preg nancy test (for women of childbearing potential),  
• AEs and SAEs since last visit will be reported in the CRF  
• Concomitant medication  will be reported in the CRF  (for details see Section 3.1.4
) 
• Return of unused med ication including empty bottles and cartons.  
All patients will have an EOS Visit (except for withdrawals and patients lost to follow -up).  
3.8.3 End-of-Study (EOS) Visit or 28-day follow- up 
Adverse events (serious or not) occurring up to [ADDRESS_448111] be followed -up for 28 days after study drug discontinuation and 
reported in the SAE form.  Liver function tests, hemoglobin assessments and pregnancy tests (for women of childbearing potential) must also be performed up to at least 28 days after study drug discontinuation. 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 37/[ADDRESS_448112] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  4 SAFETY DEFINITIONS AND REPORTING REQUIREMENTS  
4.1 Summary table  
Periods  Treatment Follow-up After follow-up 
Timeframe During study drug administration Up to 28 days after study 
drug discontinuation After 28 days  
AE/SAE reporting  on CRF AE page  All AEs/SAEs All AEs/SAEs
 None 
SAE reporting on SAE form All SAEs
 All SAEs At investigator’s 
discretion2 
Reconciliation [ADDRESS_448113] to be used to follow up on any laboratory  abnormalities after the EOS visit . 
 
4.2 Adverse events  
4.2.1 Definitions of adverse events  
An AE is any adverse change from the patient ’s baseline condition, i.e., any unfavorable 
and unintended sign including an abnormal laboratory finding, symptom or disease that  
occurs during the course of the study, whether or not considered related to the study drug.  A treatment -emergent AE is any AE temporally associated with the use of a study drug, 
whether or not considered related to the study drug.  Adverse events include: • Exacerbation of a pre- existing disease.  
• Increase in frequency or intensity of a pre -existing epi[INVESTIGATOR_42861]. 
• Disease or medical condition detected or diagnosed after study drug administration even though it may have been present pr ior to the start of the study.  
• Continuous persistent disease or symptoms present at baseline that worsen following the start of the study. 
• Lack of efficacy in the acute treatment of a life -threatening disease.  
• Events considered by [CONTACT_110190]- mandated procedures.  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 38/[ADDRESS_448114] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  • Abnormal assessments, e.g., ECG findings, must be reported as AEs if they represent a clinically significant finding that was not present at baseline or worsened during the course of the study. 
• Laboratory test abnormali ties must be reported as AEs if they represent a clinically 
significant finding, symptomatic or not, which was not present at baseline or worsened during the course of the study or led to dose reduction, interruption or permanent discontinuation of study drug. 
Adverse events do not include: • Medical or surgical procedure, e.g., surgery, endoscopy, tooth extraction, transfusion. However, the event leading to the procedure is an AE. If this event is serious, the procedure must be described in the SAE narrative.  
• Pre-existing disease or medical condition that does not worsen. 
• Situations in which an adverse change did not occurred, e.g., hospi[INVESTIGATOR_116283]/or convenience reasons.  
• Overdose of either study drug or concomitant medication without any signs or symptoms. 
4.2.2 Intensity of adverse events 
The intensity of clinical AEs is graded on a three- point scale: mild, moderate, severe.  
 Mild  
Event may be noticeable to subject; does not influence daily activities; usually does not require intervention. 
 Moderate  
Event may make subject uncomfortable; performance of daily activities may be influenced; intervention may be needed. 
 Severe  
Event may cause noticeable discomfort; usually interferes with daily activities; subject may not be able to continue in the study; treatment or intervention is usually needed. A mild, moderate or severe AE may or may not be serious. These terms are used to describe the intensity of a specific event (as in mild, moderate, or severe myocardial infarction). However, a severe event may be of relatively minor medical significance (such as severe headache) and is not necessarily serious. For example, nausea lasting several hours may be rated as severe, but may not be clinically serious. Fever of 39 °C that is not considered severe may become serious if it prolongs hospi[INVESTIGATOR_359228] a day (see Section [IP_ADDRESS]). 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 39/[ADDRESS_448115] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  Seriousness rather than sever ity serves as a guide for defining regulatory reporting 
obligations. These definitions do not apply to clinically significant and asymptomatic laboratory test abnormalities or abnormal assessments (e.g., LFT findings) considered as AEs. The investigator sh ould tick non-applicable on the AE page of the CRF to qualify the intensity 
of the AE. 4.2.3 Relationship to study drug  
Adverse events should be assessed by [CONTACT_359253] a reasonable possibility of causal relationship to the study drug and reported as either related or unrelated. 
 Related to study drug  
This category applies to any AE (serious or not) that appears to have a reasonable possibility of causal relationship to the use of the study drug (i.e., a relationship cannot be ruled out). Guidelines to determine whether an event might be considered related include (but are not limited to) the following:  
• The event occurred in close temporal relationship to study drug administration. 
• The event abated (diminished) or disappeared when treatment with the study drug was interrupted, or discontinued.  
• The event re- occurred when treatment was re-introduced. 
• Environmental factors such as clinical state and other treatments could equally have caused the event.  
 Unrelated to study drug  
This category applies to any AE (serious or not) that does not appear to have a reasonable 
relationship to the use of study drug (see above guidelines). 4.2.[ADDRESS_448116] be followed up to 28 days after study drug discontinuation. 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 40/[ADDRESS_448117] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  4.3 Serious adverse events  
4.3.1 Definitions  
[IP_ADDRESS] Serious adverse events  
A serious adverse event (SAE) is defined by [CONTACT_25039] 
(ICH) guidelines as any AE fulfilling at least one of the following criteria:  
• Fatal.  
• Life-threatening. 
• Requiring patient’ s hospi[INVESTIGATOR_1081].  
• Resulting in persistent or significant disability or incapacity.  
• Congenital anomaly or birth defect. 
• Medically significant, or requires intervention to prevent at l east one of the outcomes 
listed above. 
Life-threatening refers to an event in which the subject/patient was at risk of death at the 
time of the event. It does not refer to an event that hypothetically might have caused death if it had been more severe.  
Important medical events that may not immediately result in death, be life -threatening, or 
require hospi[INVESTIGATOR_107922], based upon appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in the definitions above.  The reference safety document to assess whether or not an SAE should be reported by [CONTACT_180515], ECs/IRBs and investigators in an expedited fashion is the Maci tentan Investigator’s Brochure [ Macitentan IB ]. 
[IP_ADDRESS] Hospi[INVESTIGATOR_059] – Prolongation of existing hospi[INVESTIGATOR_359229] a hospi[INVESTIGATOR_359230]/or emergency room due to an adverse event.  
An additional overnight stay defines a prolongation of existing hospi[INVESTIGATOR_059]. The following is not considered an SAE: • Treatment on an emergency or outpatient basis for an event not fulfilling the definition of seriousness given above and not resulting in hospi[INVESTIGATOR_059]. 
The following reasons for hospi[INVESTIGATOR_110152]/SAEs:  • Hospi[INVESTIGATOR_78429], social and/or convenience reasons.  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 41/[ADDRESS_448118] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  • Standard monitoring of a pre- existing disease or medical condition that did not 
worsen, e.g., hospi[INVESTIGATOR_42865] a patient with stable angina pectoris.  
• Elective treatment of a pre -existing disease or medical condition that did not worsen, 
e.g., hospi[INVESTIGATOR_92820], elective hip replacement for arthritis . 
[IP_ADDRESS] Serious adverse events related to study-mandated procedures  
Such SAEs are defined as SAEs that appear to have a reasonable possibility of causal relationship (i.e., a relationship cannot be ruled out) to study- mandated procedures 
(excluding administrati on of study drug) such as complication of a mandated invasive 
procedure (e.g., blood sampling, heart catheterization), or car accident on the way to the hospi[INVESTIGATOR_34092] a study visit, etc.  
4.3.2 Reporting of serious adverse events  
[IP_ADDRESS] Enrollment period  
Serious adverse events occurring from signature [CONTACT_359282] [CONTACT_110190]- mandated procedures.  
An SAE not temporally associated with the use of a study drug, should be considered by [CONTACT_359254] -related if it appears to have a reasonable possibility of relationship 
(i.e., a relationship cannot be ruled out) to protocol -mandated procedures (e.g., 
complication of a mandated invasive procedure or  car accident on the way to the hospi[INVESTIGATOR_339367] a study visit, etc.).  
These SAEs are not reported in the CRF. Therefore, they are only collected on the SAE form and entered only into the drug safety database. [IP_ADDRESS] Treatment period  
All SAEs regardless of causal re lationship must be reported, including those related to 
study- mandated procedures. These SAEs occurring between study drug initiation and up 
to [ADDRESS_448119] be reconciled before study closure. 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 42/[ADDRESS_448120] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  [IP_ADDRESS] Reporting procedures  
All SAEs must be reported by [CONTACT_269418] 24 hours of the investigator ’s knowledge of the event. 
All SAEs must be recorded on SAE forms, irrespective of the study drug received by [CONTACT_102], whether or not this event is considered by [CONTACT_7185]. These SAE forms must be faxed to Actelion Drug Safety (see SAE Form).  The investigator 
must complete the SAE form in English (unless otherwise specified) and assess the relationship to study drug. Such preliminary reports will be followe d by [CONTACT_359255][INVESTIGATOR_3103], autopsy reports, hospi[INVESTIGATOR_110160]. Follow -up information about a previously 
reported SAE must also be reported within [ADDRESS_448121] the investigator to obtain further information.  
Suspected (considered related to the study drug) and unexpected (not previously described in the reference safety document), serious adverse reactions will be expedited by [CONTACT_359256], ECs/IRBs and investigators, as appropriate. The AE/SAEs listed below are commonly seen with the underlying PAH disease. For reporting, these SAEs will be treated as “ disease- related ” and therefore will not be subject 
to regulatory expedited reporting to Health Authorities, IRBs/IECs, and investigators: Signs and symptoms of PAH include worsening/exacerbation/progression, including fatal 
outcome, heart failure, worsening right heart failu re, collapse, syncope, hemoptysis, 
anorexia, abdominal pain, chest pain, cyanosis, diaphoresis, dizziness, pre -syncope, 
hypoxia, fatigue, dyspnea, orthopnea, palpi[INVESTIGATOR_814], systemic arterial hypotension, and tachycardia. These SAEs must be reported on an SA E form and also on AE pages in the 
eCRF.  
4.3.[ADDRESS_448122] be followed until resolution or stabilization or until the event is otherwise explained.  New SAEs occurring at any tim e after the 28 -day follow -up period after study drug 
discontinuation may be reported on a SAE form to Actelion drug safety within 24  hours of 
the investigator’ s knowledge of the event, if felt appropriate by [CONTACT_473]. 
Therefore, these SAEs are ent ered only into the drug safety database and hence will not 
affect study closure.  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 43/[ADDRESS_448123] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  4.[ADDRESS_448124] counsel the patient and discuss the risks of continuing with the pregnancy and the possible effects on the fetus. Under certain circumstances, it will be acceptable for women who became pregnant during the study to remain in the study, if all of the following conditions are met: • Study drug has been withdrawn immediately after confirmation of pregnancy and 
• Absence of pregnancy is confirmed within the maximal drug interruption period, i.e., 
within 4  weeks, before study drug is re- started  and  
• Documentation of appropriate  contraceptive counseling has taken place and 
• The patient agrees to practice reliable and  effective contraception as required by [CONTACT_359257] 28 days after study 
treatment termination and  
• The re-introduction of study drug has been approved by [CONTACT_180494] 
4.4.[ADDRESS_448125] be reported within 24 hours of the investigator ’s 
knowledge of the event. Pregnancies must be reported on the Actelion Pregnancy form, which is faxed to Actelion Drug Safety  (see Pregnancy Form), and on an AE page of the CRF, as applicable. 
4.4.[ADDRESS_448126] study closure.  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 44/[ADDRESS_448127] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  5 STATISTICAL METHODOLOGY AND ANALYSES  
5.1 Statistical analysis plan  
A statistical analysis plan (SAP) will be written and finalized before  study closure, i.e., 
database closure. The SAP will provide full details of the analyses, the data displays and the algorithms to be used for data derivations.  The SAP will include the definition of major and minor protocol deviations and the link of major protocol deviations to the analysis sets.  
Before study closure, medically trained staff will identify major and minor protocol deviations.  
5.2 Analysis sets 
Two different analysis sets are defined.  
5.2.1 All-treated set  
This analysis set comprises (i) all patients in the AC -055- 303/SERAPHIN OL study plus 
(ii) all patients who received macitentan during the AC -055- 302/SERAPHIN study and did 
not participate in the AC -055-303/SERAPHIN OL study.  
This analysis set is used for the patient disposition summary.  
5.2.[ADDRESS_448128]- baseline safety assessment. Baseline is defined as the Baseline of 
AC-055- 302/SERAPHIN for the patients who received macitentan  during 
AC-055- 302/SERAPH IN and as macitentan  initiation in AC -055- 303/SERAPHIN OL for 
the patients who received placebo during AC -055-302/SERAPHIN. This analysis set is 
used as the denominator for the calculation of AE rates.  
5.3 Primary efficacy endpoint  
Not applicable. 
5.4 Secondary efficacy endpoints  
Not applicable. 
5.5 Safety and tolerability endpoints  
For a detailed description of the safety endpoints see Section  3.6.2. 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 45/[ADDRESS_448129] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  The safety set is used to perform all safety analyses.  All AEs and all SAEs are coded using the MedDRA dictionary. Treatment -emergent AEs are tabulated by [CONTACT_9313] (SOC), and individual 
preferred terms within each SOC. The incidence of patients who experienced AEs coded with the same preferred term is tabulated by [CONTACT_34689] (in descending order 
according to the incidence in the investigational study drug group). Adverse events will also be tabulated by [CONTACT_110204]. Summary tables will be accompanied by [CONTACT_359258].  Adverse events leading to premature discontinuation of study drug will be listed and summarized similarly to AEs.  
Treatment -emergent SAEs will be listed and summarized similarly to AEs, separately for 
treatment- emergen t SAEs and SAEs occurring before study drug initiation (only those 
related to study-mandated procedures) and after study drug discontinuation. Reasons for death will be listed and summarized similarly to AEs, separately for treatment emergent deaths and deaths occurring before study drug initiation (only those related to study mandated procedures) and after study drug discontinuation. Reasons for premature discontinuation of study drug will be listed and summarized by [CONTACT_47898].  
Treatment -emergent ma rked laboratory abnormalities will be summarized for each 
laboratory parameter by [CONTACT_180528]. Actelion internal guidelines will be used for the definition of marked laboratory abnormalities and for the standardization of numeric values obtained from different laboratories and/or using different normal ranges. Standard numeric laboratory parameters are transformed to standard units. Absolute values and changes during the course of the study of laboratory parameter s values converted to standardized units will be summarized by [CONTACT_359259].  
5.6 Exposure to study drug(s)  
Exposure to macitentan  will be described in terms of duration and dose. The duration o f 
exposure is defined as the time elapsing between study drug initiation and discontinuation, inclusive. The exposure time will be tabulated using the usual location and scale statistics by [CONTACT_1570]. The cumulative distribution of exposure time by [CONTACT_359260] (e.g., at least [ADDRESS_448130] 8 weeks, etc.) will be tabulated to show the number and percentage of patients in each class interval. The mean daily dose per patient is defined as the ratio between the total dose administered du ring the treatment period and the total 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 46/[ADDRESS_448131] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  exposure time. The mean daily dose is tabulated using the usual location and scale statistics by [CONTACT_1570]. 
5.7 Baseline parameters  
Continuous demographic variables (age, height, weight, others) and baseline diseas e 
characteristics will be summarized by [CONTACT_359261] (mean, median, standard deviation , Q1, Q3, minimum, and maximum).  
Qualitative demographic characteristics (gender, race, others) and baseline disease characteristics will be summarized by [CONTACT_33335].  
5.8 Exploratory analyses  
Not applicable. 
5.9 Interim analyses  
No interim efficacy analysis is planned.  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 47/[ADDRESS_448132] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  6 REFERENCES 
[Macitentan IB] Investigator’ s Brochure. Macitentan ACT -064992. Endothelin receptor 
antagonist, Version 13. Actel ion Pharmaceuticals Ltd, November 2015. 
[Abenhaim 1996] Abenhaim L, Moride Y, Brenot F, et al. Appetite- suppressant drugs and 
the risk of Pulmonary Hypertension Study group. N Engl J Med 1996; 335: 609–16. 
[Barst 2004] Barst RJ, Langleben D, Badesch D, et al. Pulmonary arterial hypertension: 
Epi[INVESTIGATOR_623], pathobiology, assessment, and therapy. JACC 2004; 43 (12): 1S –90S. 
[Battle 1996] Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary 
hypertension in limited and diffuse scleroderma. CHEST 1996; 110: 1515–9. 
[Castro 1996] Castro M, Krowka MJ, Schroeder DR, et al. Frequency and clinical 
implication of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc. 1996; 71: 543–51. 
[Chaouat 2005] Chaouat A, Bugnet AS, Kadaoui N, et al. Severe Pulmonary hypertension 
and chronic obstructive pulmonary disease. Am J Respir Crit Care med 2005; 172: 189–94. 
[Chua 1992] Chua B, Krebs CT, Chua CC, et al. Endothelin stimulates protein synthesis in 
smooth muscle cells. Am J Physiol 1992; 262: E412–6. 
[Clarke 1989] Clarke J, Benjamin N, Larkin W, et al. Endothelin is a potent long lasting 
vasoconstrictor in men. Am J Physiol 1989; 257: H2033–5. 
[D’Alonzo 1991] D ’Alonzo GE, Barst  RJ, Ayres SM, et al. Survival in patients with 
primary pulmonary hypertension – results from a national prospective registry. Ann 
Intern Med 1991; 115: 343–9. 
[Davie 2002] Davie N, Haleen SJ, Upton PD, et al. ETA and ETB receptors modulate the 
proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002; 165: 398–405. 
[de Nucci 1988] de Nucci G, Thomas R, D Orleans -Juste P, et al. Pressor effects of 
circulating endothelin are limited by [CONTACT_359262] g 
endothelin are limited by [CONTACT_359263] -derived relaxing factor. Proc Natl Acad Sci U S A 1988; 85: 9797–
800. 
[Delcroix 1998] Delcroix M, Kurz X, Wlackiers D, et al. High incidence of primary 
pulmonary hypertension associated with appetite suppressants  in Belgium. Eur 
Respir J 1998;12:271–6. 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 48/[ADDRESS_448133] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  [Fagan 2004] Fagan KA, Badesch DB. Pulmonary hypertension associated with connective 
tissue disease. In: Peacock AJ, Rubin LJ, eds. Pulmonary Circulation. London: Arnold Publishers; 2004: 181–90. 
[Farber 2004] Farber HW, Loscalzo J. Mechanisms of disease: pulmonary arterial 
hypertension. N Engl J Med 2004, 351: 1655–65. 
[FDA 2020] Food and Drug Administration. Drug Development and Drug Interactions: 
Table of  Substrates, Inhibitors and Inducers (Table 2-2). 
https://www.fda.gov/drugs/drug-interactions- labeling/drug -development-and-drug-
interactions -table -substrates -inhibitors -and-inducers. Accessed 09 July 2020. 
[Fedullo 2001] Fedullo P.F, Auger W.R, Ker K.M, et al. Chronic Thromboembolic 
Pulmonary Hypertension. N Engl J Med 2001; 345: 1465–72. 
[Fishman 1999] Fishman AP. Aminorex to fen/phen: an epi[INVESTIGATOR_359231]. Circulation 
1999; 99: 156–61. 
[Galie 2004] Galie N, Manes A, Branzi A. The endothelin system in pul monary arterial 
hypertension. Cardiovasc Res 2004; 61: 227–37. 
[Giaid 1993] Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin- 1 in 
the lungs of patients with pulmonary hypertension. N Engl J Med. 1993; 328: 1732–9. 
[Gladwin 2004] Gladwin MT, Sachdev V, Jison ML et al. Pulmonary hypertension as a 
risk factor for death in -patient with sickle cell disease. N Engl J Med 2004; 350: 886–
95. 
[Gurther 1985] Gurther HP. Aminorex and pulmonary hypertension: a review. Cor Vasa 
1985; 27: 160–71. 
[Hira ta 1993] Hirata Y, Emori T, Eguchi S. Endothelin receptor subtype B mediates 
synthesis of nitric oxide by [CONTACT_180540]. J Clin Invest 1993; 91: 1367–73. 
[Humbert 2004a] Humbert M, Morell NW, Archer SL, et al. Cellular and Molecular 
Pathobiology of pulmonary Arterial Hypertension. J Am Coll Cardiol 2004; 43: 13S –
24S. 
[Humbert 2004b] Humbert M, Sitbon O, Simonneau G. treatment of pulmonary arterial 
hypertension. N Engl J Med 2004; 351: 1425–36. 
[Kuo 1997] Kuo PC, Plotkin JS, Johnson LB, e t al. Distinctive clinical features of 
portopulmonary hypertension. Chest 1997; 112: 980–6. 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 49/[ADDRESS_448134] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  [Love 1990] Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the 
lupus anticoagulant in systemic lupus erythematous (SLE) and in non- SLE disord ers. 
Relevance and clinical significance. Ann Intern Med 1990; 112: 682–98. 
[Massaki 1998] Massaki T. The discovery of endothelins. Cardiovasc Res 1998; 39: 530–
3. 
[McGoon 2004] McGoon M, Gutterman D, Steen V, et al. Screening early detection and 
diagnosis of pulmonary arterial hypertension: ACCP evidence -based clinical practice 
guidelines. CHEST 2004; 126 (1): 14S–34S. 
[McLaughlin 2004] McLaughlin V, Presberg K, Doyle R, et al. Diagnosis and management 
of pulmonary arterial hypertension: ACCP evidence -based clinical practice 
guidelines. CHEST 2004; 126 (1): 1S–92S. 
[Mehta 2000] Mehta NJ, Khan IA, Mehta RN et al. HIV- related pulmonary hypertension: 
analytic review of [ADDRESS_448135] 2000; 118: 1133–41. 
[Opravil 1997] Opravil M, Pechere M, Speich R, et al. H IV-associated primary pulmonary 
hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med. 1997; 155: 990–5. 
[Pengo 2004] Pengo V, Lensing A.W.A, Prins M.H, et al. Incidence of chronic 
Thromboembolic Pulmonary Hypertension after  Pulmonary Embolism. N Engl J 
Med 2004; 350: 2257–64. 
[Petitpretz 1994] Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in 
patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994; 89: 2722–7. 
[Rubin 1997] Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997; 111–7. [Shorr 2005] Shorr AF, Helman DL, Davies DB, et al. Pulmonary hypertension in 
advanced sarcoidosis: epi[INVESTIGATOR_89281]. Eur Respir J 20 05; 
25: 783–8. 
[Simonneau 2004] Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of 
pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S–12S.  
[Stewart 1991] Stewart DJ, Levy RD, Cernacek  P, et al. Increased plasma endothelin- 1 in 
pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114: 464–9. 
[Sugawara 1996] Sugawara F, Ninomiya H, Okamoto Y, et al. Endothelin-1-
inducedmitogenic responses of Chinese hamster ovary expressing human endothelin 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 50/[ADDRESS_448136] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  A: the role of a wortmannin -sensitive signalling pathway. Molec Pharmacol 1996; 
49: 447–57. 
[Tanaka 2002]  Tanaka E, Harigai M, Tanaka M, et al. Pulmonary hypertension in systemic 
lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002; 29: 282–7. 
[Thabut 2005] Thabut G, Dauriat G, Stem JB, et al. Pulmonary hemodynamics in advanced 
COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127:1531–6. 
[Thomson 2003] Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary 
pulmonary hypertension is associated with germline mutation of the gene encoding BMPR- II, a receptor member of the TGF -beta family. J Med Genet. 2003; 37: 741 –
5. 
[Ungerer 1983] Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates 
of pulmonary arterial hypertension in progressi ve systemic sclerosis. Am J Med 
1983;75:65–74. 
[Weitzenblum 2005] Weitzenblum E and Chaouat A. Severe pulmonary hypertension in 
COPD: Is it a distinct disease. Chest 2005; 127: 1480–2. 
 
 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 51/[ADDRESS_448137] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  [ADDRESS_448138] been submitted to ECs/IRBs or Health Authorities. Therefore, an amendment could 
occur before or after the approval of these documents by [CONTACT_39989]/IRBs or Health Authorities . 
Each amendment must be documented in writing and approved by [CONTACT_180494]. It should be reviewed by [CONTACT_079](s) or Steering Committee, as appropriate.  
Adaptations of the core Subject/Patient Information and Informed Consent requested by [CONTACT_39989]/IRBs are not considered as amendments, as long as they do not significantly change 
the core document or affect the protocol. 
 Non-substantial amendment  
Administrative or logistical minor changes require a non -substantial amendment. Such 
changes inclu de but are not limited to changes in study staff or contact [CONTACT_8972] (e.g., 
Actelion instead of CRO monitors) or minor changes in the packaging or labeling of study drug.  The implementation of a  non- substantial amendment could be done with or without 
(acco rding to national regulations) notification to the appropriate ECs/IRBs and Health 
Authorities. It does not require their approval or to be signed by [CONTACT_473].  
 Substantial amendment  
Significant changes require a substantial amendment. Significant changes include but are 
not limited to: new data affecting the safety of subjects/patients, change of the objectives/endpoints of the study, eligibility criteria, dose regimen, study assessments/procedures, treatment or study duration, with or without the  need to modify 
the core Subject/Patient Information and Informed Consent. Substantial amendments are to be approved by [CONTACT_359264]/IRBs and in some countries by [CONTACT_217928] . The implementation of a substantial amendment  can 
only occur a fter formal approval by [CONTACT_359264]/IRBs and/or Health Authorities  
and must be signed by [CONTACT_473]. 
 Urgent  amendment  
An urgent amendment might become necessary to preserve the safety of the subjects/patients included in the study. The requirements for approval should in no way prevent any immediate action being taken by [CONTACT_359265]/patients. Therefore, if deemed necessary, an investigator can 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 52/[ADDRESS_448139] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  implement an immediate change to the protocol for safety reasons. This means that, exceptionally, the implementation of urgent amendments will occur before submission to and approval by [CONTACT_39989]/IRBs and Health Authorities.  In such cases, the investigator must no tify Actelion within 24 hours. A related substantial 
amendment will be written within 10 working days by [CONTACT_359266]/IRBs and Health Authori ties. 
7.1.[ADDRESS_448140] access to all source documents needed to verify the entries on the CRF and other protocol -related documents; provided that patient confi dentiality is maintained in 
agreement with local regulations. It will be the monitor’ s responsibility to inspect the CRF 
at regular intervals throughout the study, to verify the adherence to the protocol and the completeness, consistency and accuracy of th e data being entered on them. Actelion 
monitoring standards require full verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs and the recording of the main efficacy, safety and tolerability  endpoints. Additional checks of the consistency 
of the source data with the CRFs are performed according to the study- specific monitoring 
plan. 
The identification of any data recorded directly on the CRFs and considered to be source data are specified in the following document: “ Site Guidelines ”. The investigator must 
ensure that patients ’ anonymity will be maintained. On CRFs or other documents submitted 
to Actelion, patients should not  be identified by [CONTACT_2249], but by [CONTACT_92361]. 
The investig ator must keep a subject/ patient identification log showing the subject number, 
the subject/ patient ’s name, date of birth and any other locally accepted identifiers. 
Documents identifying the patients (e.g., patients’ signed informed consent forms) should 
not be sent to Actelion and must be kept by [CONTACT_1210]. 
The investigator and co- investigators agree to cooperate with the monitor(s) to ensure that 
any issue detected in the course of these monitoring visits are resolved. If the patient is hospi[INVESTIGATOR_42878] a hospi[INVESTIGATOR_359232], the investigator is in charge of contact[CONTACT_359267][INVESTIGATOR_359233]. The investigator shall supply Actelion on request with any required background data from the study documentation or clinic records. This is particularly important when CRFs are 
illegible or when errors in data transcription are suspected. In case of special problems and/or governmental queries, it is also necessary to have access to the complete study records, provided that patient confidentiality is protected.  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 53/[ADDRESS_448141] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  An initiation visit will be performed before the first patient is included. Monitoring visits and contacts will occur at regular intervals thereafter, according to a frequency defined in the study- specific monitoring plan. A close -out visit will be performed after study closure.  
7.1.3 Data management 
[IP_ADDRESS] Data collection 
For each patient enrolled, regardless of study drug initiation, a CRF must be completed and signed by [CONTACT_1716][INVESTIGATOR_1660] [INVESTIGATOR_1660] c o-investigator. This also applies to those patients 
who fail to complete the study. If a patient withdraws from the study, the reason must be noted on the CRF. Case report forms are to be completed on an ongoing basis. Completed CRFs will be collected by t he monitor(s).  
All forms should be completed using a digital pen (or in case it is not working a black ballpoint pen), and must be legible. Errors should be crossed out but not obliterated, the correction inserted, and the change initialed and dated by [CONTACT_11168], co -investigator 
or study nurse. [IP_ADDRESS] Database management and quality control  
All data from the CRF will be entered into the database twice, by [CONTACT_359268].  
Subsequently, the entered data is systematically checked by [CONTACT_359269], using error messages printed from validation programs and database listings. Errors with obvious corrections will be corrected and communicated to the site. Data clarification requests will be entered on Data Clarification Forms, which will be returned to the investigational site 
for resolution. A copy of the signed Data Clarification Form is to be kept with the CRFs and, once received at Actelion, the resolutions will be entered into the clinical database.  A second review of the data will be performed by [CONTACT_359270].  
Quality control audits of the database will be made before study closure.  
After the database has been declared complete and accurate, the database will be locked. Any changes to the database after that time can only be made by [CONTACT_359271]. 
7.1.[ADDRESS_448142] of the study to be fully documented a nd the study data to be subsequently verified. These 
documents will be classified into two different categories: investigator ’s file, and patient 
clinical source documents.  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 54/[ADDRESS_448143] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  The investigator ’s file will contain the protocol/amendments, FDA form 1572 for stu dies 
conducted under an US IND, financial disclosure form, CRFs and data clarification and query forms, EC/IRB and Health Authority approval with correspondence, informed consent, drug records, staff curriculum vitae and authorization forms, screening and enrollment logs, and other appropriate documents/correspondence as per ICH  / Good 
Clinical Practice (GCP) and local regulations.  
Patient clinical source documents include, but are not limited to patient hospi[INVESTIGATOR_307]/clinic records, physician ’s and nurse ’s note s, appointment book, original laboratory reports, 
ECG, X- ray, pathology and special assessment reports, consultant letters, etc.  
These two categories of documents must be kept on file by [CONTACT_96029] (generally [ADDRESS_448144] marketing approval). No study document should be destroyed without prior written approval from Actelion. Should the investigator wish to assign the study records to another party, or move them to another location, Actelion must be notified in advance. When source documents are required for the continued care of the patient, appropriate copi[INVESTIGATOR_231654]. 7.1.[ADDRESS_448145] an inspection (during the study or after its 
completion). Should an inspection be requested by [CONTACT_6628], the investigator must inform Actelion immediately that such request has been made.  
The investigator will permit suc h audits by [CONTACT_359272]. 7.1.6 Handling of study drug(s)  
Actelion will supply all study drug(s) to the site according to local regulations. Drug supplies must be kept in an appropriate, secure area and stored according to the conditions specified on the drug labels. The site must maintain an accurate record of the shipment and dispensing of study drug(s) on an accountability form, which must be given to the monitor at the end of the study. An accurate record of the date and amount of study drug(s) dispensed to each subject must be available for inspection at any time.  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 55/[ADDRESS_448146] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  All drug supplies are to be used only for this protocol and not for any other purpose. The responsible person must not destroy any drug labels, or unused drug supply. Upon termination of the study, the monitor will collect used and unused drug patient kits. They will be sent to the warehouse, where the sponsor or its deputy will check drug accountability. In certain circumstances, used and unused drug containers can be destroyed at the site once drug accountability is final and checked by [CONTACT_359273]. 7.1.[ADDRESS_448147] be published or presented 
at congresses only in their entirety and not as individual center data, except for ancillary  
studies.  
The main investigator(s) and the Steering Committee, if any, will have the opportunity to review the analysis of the data and to discuss with the sponsor the interpretation of the study results prior to publication.  
Any study- related article or abstract written independently by [CONTACT_359274] [ADDRESS_448148] similar con fidentiality from his/her staff and 
the EC/IRB. Study documents provided by [CONTACT_180494] (investigators ’ brochures, protocols, 
CRFs and other protocol -related documents) will be stored appropriately to ensure their 
confidentiality. The information provided by [CONTACT_359275], except to the extent necessary to obtain informed consent from subjects/patients who wish to participate in the trial. 
 
7.1.9 Premature termination or suspension of the study  
Both Actelion and the investigator reserve the right to terminate the study at any time.  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 56/[ADDRESS_448149] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  If a study is prematurely terminated or suspended, Actelion will promptly inform the investigators, the ECs/IRBs and Health Authorities, as appropriate, and provide the reason(s) for the termination or suspension.  If the study is prematurely terminated or suspended for any reason, the investigator in agreement with Actelion should promptly inform the enrolled subjects/patients and ensure their appropriate treatment and follow -up. 
In addition, if the investigator terminates or suspends a study without prior agreement of the sponsor, the investigator should promptly inform Actelion and the EC/IRB, and should provide the sponsor and the EC/IRB wit h a detailed written explanation of the termination 
or suspension. If the EC/IRB terminates or suspends its approval/favorable opi[INVESTIGATOR_1101] a study, the investigator should promptly notify Actelion and provide Actelion with a detailed written explanation of the termination or suspension. 
Any premature termination or suspension of the study must be discussed with the Steering Committee as appropriate.  
7.2 Good Clinical Practice  
7.2.1 Ethics and Good Clinical Practice  
The investigator will ensure that this study is conducted in full conformance with the principles of the “ Declaration of Helsinki” and with the laws and regulations of the country 
in which the clinical research is conducted. A copy of the Declaration of Helsinki will be provided in the investigator site.  All studies must follow the ICH GCP Guidelines and, if applicable, the Code of Federal 
Regulations. In other countries in which GCP Guidelines exist, the investigators will strictly ensure adherence to the stated provisions.  
7.2.2 Ethics Committee / Institutional Review Board  
The investigator will submit this protocol and any related document provided to the patient (such as patient information used to obtain informed consent) to an Ethics Committee (EC) or Institutional Review Board (IRB). Approval from the commit tee must be obtained 
before starting the study, and should be documented in a dated letter to the investigator, 
clearly identifying the trial, the documents reviewed and the date of approval. A list of members participating in the meeting must be provided,  including the functions of these 
members. If study staff staff were present, it must be clear that none of these persons voted.  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 57/[ADDRESS_448150] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  Modifications made to the protocol after receipt of the EC/IRB approval must also be submitted as amendments by [CONTACT_359276]/IRB in accordance with local procedures and regulations (see Section 7.1.1).  
7.2.[ADDRESS_448151] also explain to the patients that they are completely free to refuse to enter the study or to withdraw from it at any time for any reason. Appropriate forms for documenting written informed consent will 
be provided to the sites prior to the study. The Informed Consent and Patient Information will be provided in the local language.  
7.2.4 Compensation to subjects and investigators 
The sponsor is providing insurance in order to indem nify (legal and financial coverage) the 
investigator/center against claims arising from the study, except for claims that arise from malpractice and/or negligence.  
The compensation of the subject/patient in the event of study- related injuries will comply 
with the applicable regulations.  
  
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 58/[ADDRESS_448152] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  8 APPENDIX  
Appendix 1 : Protocol Amendment History  
The Protocol Amendment Summary of Changes Table for the current amendment is located directly before the Table of Contents. Summary of previous ame ndments is 
provided below.  
Amendment  Date  Main reason(s)  
1 15-Nov-2007  Non-substantial amendment : As only macitentan is to be 
administer ed, the reference to placebo  / treatment code 
break in affected sections has been removed.   
As local laboratories will be used for blood and urine tests, reference to central laboratory has been removed.  
2 18-Jul-2008  Substantial amendment : Addition of CYP3A inducers to 
the list of prohibited concomitant medication. 
Definition of certain SAEs (expected i n a PAH 
population) which will not require immediate reporting to Actelion Global Drug Safety on an SAE form unless the 
event is fatal.  
3 22-Sep-2009  Substantial amendment : Increase in sample size from 
[ADDRESS_448153] for a weekly rather than bi -weekly follow -up of subjects with 
elevated liver transaminases.  
4 27-Aug-2013  Substantial amendment:  In order to facilitate the 
evaluation of the safety and tolerability data all 
concomitant treatments taken during the study will be 
collected.  
In accordance with the draft FDA “ Guidance for Industry 
Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Post -
approval Clinical 
Investigations” (February 2012), to better characterize 
safety and tolerability of macitentan , a central l aboratory 
Macitentan/ACT-064992 Pulmonary arterial hypertension  
Protocol AC -055-303/SERAPHIN OL  
Version 7 
17 July 2020 , page 59/[ADDRESS_448154] No 2007 -003694 -27 
Doc No D- 20.250 
 
CONFIDENTIAL – FOIA Exemptions Apply in U.S.  Amendment  Date  Main reason(s)  
will be used for prospective biochemistry and hematology 
analysis.  
An Independent Liver Safety Board is established to 
monitor the liver safety of macitentan including reviewing 
cases of confirmed elevations of aminotransferases > 3×  
ULN. 
[ADDRESS_448155] (LFT) monitoring in SERAPHIN -OL 
considering safety data from available macitentan 
exposure data. 
 
 
 CONFIDENTIAL – FOIA Exemptions Apply in U.S.  1 
Status: Approved , Date:  1 July 2020 Actelion Pharmaceuticals Ltd  
Janssen Research & Development *  
 
Clinical Protocol  
 
COVID -19 Appendix  
 
Protocol Title  
Long -term single -arm open -label extension study of the SERAPHIN study, to assess the 
safety and tolerability of macitentan/ACT 064992 in patients with symptomatic pulmonary 
arterial hypertension  
 
SERAPHIN OL  
 
Protocol  AC-055-303; Phase 3 
 
JNJ-67896062 /ACT -064992  Macitentan   
 *Janssen Research & Development is a global organization that operates through different legal entities in various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development studies may vary, such as, but not limited to  Actelion Pharmaceuticals Ltd, Janssen Biotech, Inc.; Janssen 
Products, LP; Janssen Biologics, BV; Janssen -Cilag International NV; Janssen, Inc; Janssen Pharmaceutica 
NV; Janssen Sciences Ireland  UC; Janssen Biopharma Inc.; or Janssen Research & Development, LLC. 
The term “sponsor” is used throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact [CONTACT_12944].  
 
[LOCATION_002] (U S) sites of t his study will be conducted under US Food & Drug Administration 
Investigational New Drug ( IND) regulations (21 CFR Part 312).] 
 EudraCT N umber : 2007-003694- 27 
Status:  Approved   
Date:  1 July 2020  
Prepared by:   [CONTACT_215197], a division of Janssen Research & Development   
EDMS number:   D-20.229  
 THIS APPENDIX APPLIES TO ALL CURRENT APPROVED VERSIONS OF PROTOCOL  
 
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory requirements.   
Confidentiality Statement 
The information provided herein contains Company trade secrets, commercial or financial information that the Company customarily holds close and treats as confidential.  The information is being provided under the assurance that the recipi[INVESTIGATOR_359234], regulations, rules, protective orders or othe rwise. 
[STUDY_ID_REMOVED]
COVID -19 Appendix   
JNJ-67896062/ACT -064992 Macitentan   Clinical Protocol  AC-055-303  
 CONFIDENTIAL – FOIA Exemptions Apply in U.S.  2 
Status: Approved , Date:  [ADDRESS_448156] DURING THE COVID- 19 PANDEMIC 
It is recognized that the Coronavirus Disease 2019 (COVID -19) pandemic may have an impact on 
the conduct of this clinical study due to, for example, self -isolation/quarantine by [CONTACT_90830]- site personnel; travel restrictions/limited access to public places, including hospi[INVESTIGATOR_600]; study 
site personnel being reassigned to critical tasks.  
In alignment with recent health authority guidance, the sponsor is providing options for study related participant management in the event of disruption to the conduct of the study. This guidance does not supersede any local or government requirements or the clinical judgement of the investigator to protect the health and well -being of part icipants and site staff. If, at any time, a 
participant’s safety is considered to be at risk, study intervention will be discontinued, and study follow -up will be conducted. 
Scheduled visits that cannot be conducted in person at the study site will be perf ormed to the extent 
possible remotely/virtually or delayed until such time that on -site visits can be resumed. At each 
contact, participants will be interviewed to collect safety data. Key efficacy endpoint assessments should be performed if required and a s feasible. Participants will also be questioned regarding 
general health status to fulfill any physical examination requirement.  Every effort should be made to adhere to protocol -specified assessments for participants on study 
intervention, including fol low up. Modifications to protocol -required assessments may be 
permitted via COVID -19 Appendix after consultation with the participant, investigator, and the 
sponsor. Missed assessments/visits will be captured in the clinical trial management system for 
protocol deviations. Discontinuations of study interventions and withdrawal from the study should be documented with the prefix “COVID -19-related” in the case report form (CRF).  
The sponsor will continue to monitor the conduct and progress of the clinical study, and any changes will be communicated to the sites and to the health authorities according to local guidance.  If a participant has tested positive for COVID 19, the investigator should contact [CONTACT_456]’s responsible medical officer to discuss plans for study intervention and follow -up. Modifications 
made to the study conduct as a result of the COVID -19 pandemic should be summarized in the 
clinical study report.  
  
COVID -19 Appendix   
JNJ-67896062/ACT -064992 Macitentan   Clinical Protocol  AC-055-303  
 CONFIDENTIAL – FOIA Exemptions Apply in U.S.  3 
Status: Approved , Date:  1 July 2020 GUIDANCE SPECIFIC TO THIS PROTOCOL  
• Scheduled Visits  
In the event that a subject is unable to come to the site due to COVID -19-related restrictions 
for a protocol- required visit, the visit may be conducted by [CONTACT_359277], when 
permitted by [CONTACT_359278]. The date of the phone call should be recorded as the visit date. If  a visit is conducted by [CONTACT_359279] a minimum data 
should be recorded for the following in the CRF:  
- Adverse event ( AE) 
- Serious AE  
- Concomitant therapy  
- Pregnancy test results (as applicable for women of chi ldbearing potential) 
In the event that a subject cannot come to the site for laboratory safety tests  due to 
COVID-19- related restrictions , required tests may be conducted at a certified local laboratory . 
If samples are analyzed by a local laboratory, resul ts, including units and normal ranges, must 
be recorded in the CRF. The investigator must review all safety assessments to confirm that 
the participant can pursue his/her study treatment. If the safety assessments cannot be performed and reviewed by [CONTACT_9916] a timely manner, the investigator may decide to interrupt or permanently discontinue study intervention, if it is in the best interest s of the 
participant.  
For women of childbearing potential, monthly pregnancy tests are required. Pregnancy t est 
kits to be used at home were provided per protocol.  
• Missed visits and/or assessments  
If a visit is missed entirely due to COVID -19-related restrictions (no site visit or phone visit 
performed), it will be captured as a protocol deviation in the clinic al trial management system 
with the prefix “COVID -19-related”.  
Missed assessments will be captured in the clinical database as protocol deviations with the 
prefix “ COVID- 19 related ”. 
In the exceptional situation that l aboratory or pregnancy tests are missed or delayed due to the 
COVID- 19 pandemic , they will be identified in the clinical database as protocol deviations 
with the prefix “COVID -19 related”. 
• Investigational Medical Product (IMP)  
In the event that a subject cannot come to the site  due to COVID-19- related restrictions  to 
receive IMP, a caregiver or family member may pi[INVESTIGATOR_359235]. 
This must first be discussed with the subject and the conversation must be documented in the subject source records. The subject must name [CONTACT_359283][INVESTIGATOR_359236]. Identification of the person who pi[INVESTIGATOR_359237]. If no other alternative is feasible, direct- to-patient (DTP) shipment of study drug from the site 
may be considered with prior approval from the sponsor. Site staff need to obtain permission from the subject and record this in the subject source record for DTP shipments. DTP shipments must be done in accordance with local regulations. 
COVID -19 Appendix   
JNJ-67896062/ACT -064992 Macitentan   Clinical Protocol  AC-055-303  
 CONFIDENTIAL – FOIA Exemptions Apply in U.S.  4 
Status: Approved , Date:  [ADDRESS_448157] be returned to the site for treatment accountability.  
• Informed Consent  
An informed consent form ( ICF) addendum will be prepared outlining the above mitigations . 
If allowed by [CONTACT_14306] / Institutional Review Board / Ethics Committee , verbal 
consent is acceptable and must be documented in the subject source notes. Documentation of verbal consent must include who consented, when they were consented, what they were told at the time, how they consented ( eg, telephone, etc), who captured the oral/verbal consent 
(including signature [CONTACT_359284]), and the  
identification of an impartial w itness who was present at the time of consent , as well as how 
the impartial witness was selected.  
• Statistical Analysis  
The s ponsor will evaluate the totality of impact of COVID -19 on collection and missingness 
of key study data and the need for additional data analyses, which will be added to the clinical 
study report and s tatistical analysis plan.  
  
COVID -19 Appendix   
JNJ-67896062/ACT -064992 Macitentan   Clinical Protocol  AC-055-303  
 CONFIDENTIAL – FOIA Exemptions Apply in U.S.  5 
Status: Approved , Date:  [ADDRESS_448158] of the study, and the obliga tions 
of confidentiality.  
Coordinating Investigator (where required):   
Name (typed or printed):   
Institution and Address:   
  
  
  
Signature:   [CONTACT_1782]:   
   (Day Month Year)  
 
Principal (Site) Investigator:   
Name (typed or printed):   
Institution and Address:   
  
  
  
Telephone Number:   
Signature:   [CONTACT_1782]:   
   (Day Month Year)  
 
Sponsor's Responsible Medical Officer:   
Name (typed or printed):  Wassim Fares  
Institution:  Actelion Pharmaceuticals Ltd, a division of Janssen Research & Development  
Signature:  [CONTACT_1782]:   
  (Day Month Year)  
 Note:  If the address or telephone number of the investigator changes during the course of the study, written 
notification will be provided by [CONTACT_68477], and a protocol amendment will not be required.  
 
[COMPANY_003]